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ABSTRACT
Drug toxicity may cause liver injury, resulting in damage to cells and tissues. This
damage can lead to cytotoxic events that may result in an activation of poly(ADP-ribose)
polymerase (PARP). A study was conducted to determine if cocaine and acetaminophen toxicity
lead to DNA damage and to the activation of the repair protein, PARP in the liver using the
hepatotoxicants: cocaine and acetaminophen (APAP).
A dose-response analysis for cocaine concluded that a dose as low as 20 mg/kg resulted
in elevated ALT levels. A higher dose of 60 mg/kg was tested for analyses but resulted in severe
hemorrhaging. The dose-response analyses for APAP resulted in no elevated liver enzyme levels
for a 75 mg/kg and 150 mg/kg dose. A dose of 50 mg/kg for cocaine, and a dose of 300 mg/kg
for APAP, were used to analyze temporal trends for both toxicants. Both cocaine and APAP
produced incremental increases in ALT at the 2 hour, 6 hour, 18 hour, and 24 hour time points,
respectively. PARP activity analysis for cocaine measured the highest activity at the 2 hour and 6
hour time points. PARP analysis for acetaminophen measured gradual increases until the 18 hour
time point where the highest level of PARP activity was measured.
A PARP inhibition analysis was conducted with cocaine and (APAP) to understand the
impact of a PARP inhibitor, 1,5-dihydroxyisoquinoline (DIQ), on PARP activity in the liver. A
50 mg/kg dose of cocaine or a 300 mg/kg dose of APAP was administered, followed by a 10
mg/kg dose of DIQ at 1) the time of initial toxicant dose (0 hour), or 2) 1 hour after initial

x

toxicant dose (1hr). The PARP inhibition analysis for cocaine and APAP was conducted at 6 and
18 hours post initial dose, respectively, when the highest levels of PARP were observed.
Inhibition analyses determined that ALT declined significantly when DIQ was administered
immediately following the initial toxicant dose for both toxicants. DIQ administered 1 hour after
initial toxicant dose resulted in slightly higher ALT than the 0 hour time point. Decreases in
PARP activity were observed at the 0 hour time point, with slightly higher PARP levels observed
at the 1 hour time point. Decreased PARP activity was observed following DIQ treatment with
both, a concurrent drug treatment and treatment following drug administration. Cocaine and
APAP treatment did not cause DNA fragmentation. A liver glutathione (GSH) analysis
conducted for cocaine and APAP did not correlate with DIQ alteration of PARP activity. The
mechanism of DIQ effects on drug-induced hepatotoxicity appears to be GSH independent. DIQ
was effective in reducing drug-induced hepatotoxicity and preserving organ function.

xi

CHAPTER ONE:
INTRODUCTION

Recent data reported by the CDC states that drug overdose was the leading cause of death
among adults aged 25-64 years old, causing more overall deaths than motor vehicle accidents
(Centers for Disease Control and Prevention, 2015). While drug overdose is on the rise among
the adult population within the United States, the use of prescription drugs has drove the recent
statistics for both drug usage, as well as drug overdose to alarming heights. However, the debate
continues to exist as to how much of a role does pharmaceutical and recreational drugs
contribute to these alarming statistics.
A drug is defined as any chemical compound that may be used for treatment or diagnosis
of a condition or disease, for pain relief, or for the feeling that it causes (CDC, 2015). It is the
misuse of drugs that lead to a potential overdose. During an overdose, an excessive amount of a
drug may be ingested, inhaled, or absorbed that may lead to body injury (CDC, 2015). Two
major classes of drugs that may lead to a potential overdose are recreational and pharmaceutical
drugs. Recreational drugs are those drugs that are used without medical justification for the
effects that they elicit (Merriam-Webster, 2015). These drugs may be habit-forming or addictive.
Some examples of recreational drugs include cocaine, amphetamines, methamphetamines, LSD,
heroin, cannabis, and ecstasy. Pharmaceutical drugs are those drugs that are prescribed and are
considered to be safe and effective (World Health Organization, 2015). Some examples of

pharmaceutical drugs include Acetaminophen, Ranitidine, Diazepam, Naproxen, and
Furosemide. An overdose of either a recreational or pharmaceutical drug may lead to a number
of adverse health effects, including acute liver injury (CDC, 2015; WHO, 2015).
As of 2007, the Centers for Disease Control and Prevention reported that as many as 120
people die per day as a result of drug overdose (CDC, 2015). This alarming statistic includes
both prescription drug abuse as well as recreational drug use. In 2012, drug overdose was the
leading cause of injury death. Overdosing of drugs led to more deaths than motor vehicle traffic
crashes among individuals between the ages of 25 to 64 (CDC, 2015). With the risk for death
from overdose increasing each year, it is imperative that research studies are conducted to
determine any potential way that we may combat these alarming death statistics.

Statement of the Problem
With recent increases observed in the number of individuals overdosing on prescription
drugs, there has also been an increase in the usage of recreational drugs as well (CDC, 2015).
The age of drug usage for recreational drugs continues to decrease every year. While youth have
the lowest death rates from drug overdose, drug abuse among all ages contributed to more than
2.5 million visits in the emergency room in 2012 (CDC, 2015). One of the major recreational
drug’s that is gaining popularity among youth in grades eight through twelve is cocaine. What is
more alarming about the use of cocaine among the youth population is that the usage of crack
cocaine far surpasses the usage of cocaine among young people (CDC, 2015; National Institute
on Drug Abuse, 2015). As of 2014, there has been a recent increase in the usage of crack cocaine
among youth aged 12 to 17 years of age (NIDA, 2015). While the physiological impacts from
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cocaine are much more acute, extensive liver damage may result from consuming high doses of
this recreational drug (McCluskey, Harbison, Sava, Johnson, Harbison, 2012; NIDA, 2015).
While prescription drug abuse may contribute the overwhelming majority of
pharmaceutical drug abuse, over the counter drugs also contribute to the recent increase in the
number of overdoses from pharmaceutical products. One of the major reasons for increase in
abuse of pharmaceutical drugs is due to the idea that pharmaceutical drugs pose less of a health
risk because they are prescribed medications (CDC, 2015; NIDA, 2015). Pharmaceutical drugs
are seen as safe and present less addictive properties as opposed to recreational drugs (CDC,
2015). However, it is this false misconception that leads to the misuse and abuse of
pharmaceutical drugs. Just as this misconception is prevalent among prescription drug abusers,
this theory also resonates for abuse of over-the-counter drugs as well. Acetaminophen, also
known as Tylenol, is commonly used as a prescribed medication, as well as an over-the-counter
drug. A common analgesic or pain reliever, acetaminophen is one of the most commonly used
pharmaceutical drugs on the market today (United States National Library of Medicine, 2015).
Because acetaminophen is an over-the-counter drug, it is deemed safe if the recommended dose
is consumed. However, acetaminophen is not recommended for large consumption with a single
dose, or for long-term usage due to its potential to cause extensive damage to the liver (United
States National Library of Medicine, 2015). It is this concern that leads to precaution of
physicians and other health professionals for consumers that may misuse this pharmaceutical
drug.

Purpose of the Study
The purpose of this study is to determine the impacts of a pharmaceutical drug and
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recreational drug overdose on the role of poly(ADP-Ribose) polymerase (PARP) protein activity
in the liver. The pharmaceutical drug acetaminophen and the recreational drug cocaine will be
used to characterize the role of PARP in hepatotoxicity. A dose-response analysis will be
conducted to determine the optimal dose to elicit cytotoxicity in the liver caused by an overdose
of cocaine and acetaminophen. A temporal analysis will be conducted to understand the role of
time in drug-induced hepatotoxicity for the two hepatotoxicants. PARP activity will be measured
to characterize the role of PARP in cocaine and acetaminophen-induced hepatotoxicity and the
onset of change. Lastly, an efficacy study inhibiting PARP activity with 1,5dihydroxyisoquinoline (DIQ) will be conducted to determine if there is a measurable reduction in
damage from blocking activation of the PARP protein.
The ability to inhibit the PARP activation mechanism will help to increase the amount of
time an individual will have to seek medical attention following an overdose. This will help to
potentially decrease mortality rates for drug overdose if an individual is able to seek medical
attention soon after administration of the drug. Furthermore, this will also help to better
understand the cytotoxic impacts of acetaminophen and cocaine in the liver, while also
explaining PARP protein activity in the liver in the presence of these known hepatotoxicants.
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CHAPTER TWO:
LITERATURE REVIEW

Cocaine Background
Cocaine is one of the most commonly used recreational drugs, with only marijuana and
heroin usage being more common among drug abusers of illicit drugs (NIDA, 2015). Some
alternative names for cocaine include coke, blow, powder, and snow (NIDA, 2015). Common
uses include the form of both cocaine and crack cocaine. Classified as a stimulant, cocaine
produces a temporary increase in functionality due to its impact on the neurotransmitter
dopamine (NIDA, 2015). The use of cocaine blocks the dopamine transporter and prevents the
reuptake of dopamine (Siegel, 1991). Cocaine produces an overproduction of dopamine, but
those dopamine molecules have nowhere to go so they bounce around between the pre- and postsynapses at the synaptic cleft (Siegel, 1991). In turn, this reaction contributes to the excitatory or
stimulatory feelings observed after consumption of the drug.
Cocaine originates from the coca plant found mostly in South America. Historically,
cocaine was used as a common anesthetic, particularly during nasal surgery (Kester, Vrana, &
Karpa, 2012). Common routes of administration include chewing, insufflation (snorting),
inhalation (smoking), dermal, and intravenous. Injecting cocaine or smoking cocaine will
provide a quicker and stronger but short lasting high as opposed to insufflation or snorting
cocaine (NIDA, 2015). A common treatment method for an overdose of cocaine is the
5

administration of Diazepam or other benzodiazepines. Administration of Diazepam is used to
treat symptoms such as elevated heart rate and blood pressure but will not alter hepatotoxicity
(NIDA, 2015).
While there are a number of potential routes of administration for cocaine, the end result
is significant impacts on the central nervous and cardiovascular system (Mehanny, AbdelRahman, 1991; Kulberg, 1986; Thompson, Shuster, Shaw, 1979; Labib, Turkall, Abdel-Rahman,
2002; Ascenzi, Clementi, Polticelli, 2003). The binding of cocaine to dopamine receptors
produces a stimulatory response due to the inhibition of the re-uptake of dopamine from the
synaptic cleft. The lack of binding of 3dopamine to its receptors produces feelings of euphoria
(Xu et al., 1994). The stimulatory effects of cocaine on the heart may severely impact heart rate
and blood pressure, along with causing damage to heart cells by reactive oxygen species
(Kovacic, 2005; Labib, Turkall, Abdel-Rahman, 2002).
Cocaine is primarily metabolized in the liver and produces two major metabolites of
ecgonine methyl ester and benzoylecgonine (Labib, Turkall, Abdel-Rahman, 2002; Stewart,
Inaba, Lucassen, Kalow, 1979; Ascenzi, Clementi, Polticelli, 2003; Stewart, Inaba, Lucassen,
Kalow, 1979). (See Figure 1.) During hepatotoxic events minor metabolites such as norcocaine
or cocaethylene are produced. Ecgonine methyl ester is metabolized via a deesesterification
metabolic pathway, while the more common metabolite benzoylecgonine is metabolized via a
demethylation metabolic pathway. Benzoylecgonine is unlikely to produce any reactive species
that may be detectable within the liver (Kovacic, 2005; Labib, Turkall, Abdel-Rahman, 2002;
Freeman and Harbison, 1981; Boess, Ndikum-Moffor, Boelsterli, Roberts, 2003vira). One minor
oxidative metabolic route producing norcocaine may produce a number of byproduce such as
nococaine nitroxide, N-hydroxynorcocaine, norcocaine nitrosonium, cocaine iminium, N6

Figure 1. Cocaine Metabolites. Metabolism of cocaine produces the metabolites of ecgonine
methyl ester, benzoylecgonine, norcocaine, and cocaethylene (Stewart, Inaba, Lucassen, Kalow,
1979; Ascemzi, Clementi, Polticelli, 2003; Thompson, Shuster, Shaw, 1979; Roth, Harbison,
James, Tobin, Roberts, 1992; Kovacic, 2004).

hydroxy, and formaldehyde, which have been shown to affect cocaine toxicity (Kovacic, 2005;
Labib, Turkall, Abdel-Rahman, 2002; Thompson, Shuster, Shaw, 1979). The production of
cocaethylene as a minor metabolite may result from cocaine metabolism in the presence of
alcohol (Ascenzi, Clementi, Polticelli, 2003). These metabolites may react with a number of
enzymes throughout the body to impact several different organ systems such as the central
nervous system and the cardiovascular system (Kovacic, 2005; Labib, Turkall, Abdel-Rahman,
2002).

Acetaminophen Background
Acetaminophen is a common analgesic drug used safely at therapeutic doses, but may
7

cause liver injury with an overdose (James, Mayeux, Hinson, 2003; Dӧnmez, Uysal, Poyrazoglu,
Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015). A common over-the-counter drug suggested for
women during pregnancy, acetaminophen is rarely recognized as a toxic drug. Common routes
of administration include intravenously, orally, and rectally. Acetaminophen overdose is one of
the leading causes of acute liver injury (McGill, Lebofsky, Norris, Slawson, Bajt, Xie, Williams,
Wilkins, Rollins, Jaeschke, 2013; Lee, 2004; Yaman, Isbilir, Cakir, Uysal, 2011). While
acetaminophen overdose may cause acute liver injury, it is unlikely to cause widespread liver
damage that could result in a liver transplant. Due to the acute impacts of acetaminophen liver
injury resulting from an overdose, it is important to use proper clinical diagnostic tests to identify
acetaminophen hepatotoxicity (Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim,
Korkmaz, 2015; Yaman, Isbilir, Cakir, Uysal, 2011). Delayed symptoms from an overdose
include nausea and vomitting that may develop more than eight hours after ingestion (Rumack,
1983). Common treatments for an overdose include charcoal and N-acetylcysteine, the latter
commonly used in Europe (Linden & Rumack, 1984; Rumack, 1983).
With origins dating back well over 100 years, acetaminophen has been a commonly used
analgesic for a number of medical conditions (Brune, Renner, Tiegs, 2015; Spooner & Harvey,
1976). Originating in a laboratory from p-nitrophenol, paracetamol gained more popularity
overseas than in the United States. It wasn’t until its efficacy as an analgesic was recognized in
the mid-1900s that acetaminophen gained widespread use in the United States (Spooner &
Harvey, 1976; Black, 1984). A patent was granted for acetaminophen use in the United States
during the 1980s (Black, 1984).
Because acetaminophen is a common analgesic, resultant target areas may vary
throughout the body (Rumack, 1983; Linden & Rumack, 1984; James, Mayeux, Hinson, 2003).
8

When taken as a therapeutic drug, acetaminophen has little to no toxic impacts on the body as
most of it metabolites are excreted in the urine (Miners, Osborne, Tonkin, Birkett, 1992). It is in
the presence of an overdose when symptoms may be observed in an individual that may require
medical attention (Budnitz, Lovegrove, Crosby, 2011). During an overdose, hepatotoxic events
may produce widespread liver damage (Shi et al., 2012; James, Mayeux, Hinson, 2003;
Jaeschke, McGill, Williams, Ramachandran, 2011; McGill, Sharpe, Williams, Taha, Curry,
Jaeschke, 2012). While charcoal and N-acetylcysteine may be used for treatment of an acute
overdose, often prolonged therapeutic use of acetaminophen may also result in widespread liver
damage as well. Resultant liver damage from acute and chronic use may be irreversible in
extreme cases (McGill et al., 2013; Williams, Koerner, Lampe, Farhood, Jaeschke, 2011;
Jaeschke, McGill, Williams, Ramachandran, 2011; McGill, Sharpe, Williams, Taha, Curry,
Jaeschke, 2012).
The complex mechanism for acetaminophen has been researched for a number of years
due to the impacts of intermediate metabolites on various cells and tissues throughout the body
(McGill, Williams, Xie, Ramachandran, Jaeschke, 2012; Gujral, Knight, Farhood, Bajt,
Jaeschke, 2002; James, Mayeux, Hinson, 2003; McGill et al., 2013; Lawson, Fisher, Simmons,
Farhood, Jaeschke, 1999). Acetaminophen metabolism occurs via three pathways. The two most
common pathways include glucuronidation and sulfation (Kessler, Kessler, Auyeung, Ritter,
2002; McGill, Sharpe, Williams, C., Taha, M., Curry, S., Jaeschke, H., 2012; Koch-Weser, 1976;
Miners, Penhall, Robson, Birkett, 1988). (See Figure 2.) The minor third metabolic pathway
involves the oxidation of acetaminophen molecules that are produced by cytochrome -P450
enzymes to produce the reactive metabolite of N-acetyl-p-benzoquinone imine (NAPQI)
(Manyike, Kharasch, Kalhorn, Slattery, 2000). Glutathione (GSH) detoxifies NAPQI molecule
9

Figure 2. Acetaminophen Metabolism. Metabolism of acetaminophen produces metabolites via
the processes of glucuronidation and sulfation, along with the formation of the reactive
metabolite N-acetyl-p-benzoquinone imine (NAPQI) (Food and Drug Administration, 2002;
James, Mayheux, Hinson, 2003; Jaeschke, McGill, Williams, Ramachandran, 2011).

through a conjugation reaction to reduce damage to liver cells and tissue from toxic metabolites
(McGill, Sharpe, Williams, C., Taha, M., Curry, S., Jaeschke, H., 2012; Nelson, 1990; Williams,
Koerner, Lampe, Farhood, Jaeschke, 2011; Cohen, Pumford, Khairallah, Boekelheide, Pohl,
Amouzadeh, Hinson, 1997; Manyike, Kharasch, Kalhorn, Slattery, 2000; Mitchell, Jollow,
Potter, Davis, Gillette, Brodie, 1973).

Hepatotoxicity
Hepatotoxic events may result from a number of acute and chronic drug use. While
10

chronic usage is a repeated use of drugs over a prolonged period of time, toxicity resulting from
acute usage may occur from consumption of a single dose of a drug. Both chronic and acute drug
usage may result in drug-induced liver injury (Begriche, Massart, Robin, Borgne-Sanchez,
Fromenty, 2011; Björnsson, 2009). However, it is the metabolism of the drug to its toxic
metabolites that may create widespread liver damage. Two common outcomes resulting from
drug toxicity are apoptosis and necrosis. Both outcomes impact cell signaling and result in
extreme damage to liver cells and tissues (Gujral, Knight, Farhood, Bajt, Jaeschke, 2002; Hong,
Dawson, Dawson, 2004; El-Hassan et al., 2003; Adams et al., 2001).
Toxicity in the liver may be measured a number of different ways. The most common
method for determining liver damage is through the testing of serum biomarkers. Abnormal
levels of serum biomarkers may provide an indirect indication of potential liver damage that may
exist (Ozer, Ratner, Shaw, Bailey, Schomaker, 2008; Amacher, 1998; Amacher, Alder, Hearth,
Townsend, 2005; Boone et al., 2005; Ramaiah, 2007). Considered the gold standard for detection
of liver injury, alanine aminotransferase (ALT) is the most frequently used serum biomarker for
assessing hepatotoxic effects (Ozer, Ratner, Shaw, Bailey, Schomaker, 2008; Amacher, 1998;
Amacher, 2002). Similar to ALT, aspartate aminotransferase (AST) is considered the second
most common serum biomarker used for measuring hepatotoxicity (Ozer, Ratner, Shaw, Bailey,
Schomaker, 2008). Although AST is less specific than ALT, abnormalities with both liver
enzymes indicate potential liver damage that may exist. Some other common serum biomarkers
used to determine hepatotoxicity include bilirubin, bile acids, gamma-glutamyl transferase, and
glutamate dehydrogenase (Ozer, Ratner, Shaw, Bailey, Schomaker, 2008; Amacher, 2002). Most
liver enzyme assays may be conducted with colorimetric detection methods, more in-depth
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ELISA assays may be used to determine any abnormalities for any non-colorimetric biomarkers
(Ozer, Ratner, Shaw, Bailey, Schomaker, 2008).

Apoptosis
A cellular pathway ending in apoptosis may result from a number of potential metabolic
pathways. Common apoptotic pathways may result from minor cellular damage to improper cell
signaling. An alternative result from apoptosis is the activation of initiator and effector caspase.
Irrespective of the mechanistic pathway, the ending result for apoptotic signaling is cell death.
Cells processing through apoptotic pathways result in cell shrinkage and cell phagocytosis while
the cell membrane remains intact (Alison, Sarraf, 1992: Sen, 1992; Proskuryakov,
Konoplyannikov, Gabai, 2003). Other metabolic processes impacted by apoptosis include DNA
fragmentation and caspase (Jaeschke, H., Cover, C., Bajt, M., 2006; McGill, Sharpe, Williams,
Taha, Curry, Jaeschke, 2012; Cohen, 1997; Sen, 1992). While cell death may be the ultimate
outcome from apoptotic signaling, often the damage to tissues is not widespread (Sen, 1992).

Necrosis
An alternative cellular pathway ending is via necrosis. A necrotic pathway is more severe
in that the cellular and tissue damage is widespread than for apoptosis. While cells may shrink
and die with apoptosis, during necrosis cells swell and burst. This potential outcome leads to
breaking of the cell membrane and cell contents are released from inside the cell causing massive
widespread tissue damage (Hong, Dawson, Dawson, 2004; Walker, Harmon, Gobé, Kerr, 1988).
Some outcomes that may result from a necrotic pathway may include ATP depletion, free
radicals, and reactive oxygen species (Jaeschke, H., Cover, C., Bajt, M., 2006; McGill, Sharpe,
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Williams, Taha, Curry, Jaeschke, 2012; Begriche, Massart, Robin, Borgne-Sanchez, Fromenty,
2011). A necrosis ending result is more detrimental to cells and tissues due to the widespread
damage that is caused with the bursting of cells and the release of free radicals to potentially
generate further damage to other nearby cells (Proskuryakov, Konoplyannikov, Gabai, 2003).

Other Outcomes of Hepatotoxicity
There are a number of outcomes that may result from potential hepatotoxic events. Each
of the resultant outcomes result in either necrosis or apoptosis as damage to cells and tissues
occur. Some common alternative outcomes that may result from hepatotoxic events include
DNA fragmentation, activation of caspases, and ATP depletion. Activation of any of these
processes will most likely result in cell death and tissue damage. Most damage that occurs as a
result of these outcomes is irreversible.
DNA fragmentation expresses the cleaving of DNA that occurs during apoptotic
signaling. Apoptotic signaling causes histones wrapped around DNA to unravel and expose
DNA strands. Exposed strands are susceptible to degradation as other parts of the cell die during
the apoptosis process. Another potential outcome leading to apoptosis that may arise from an
apoptotic pathway is the activation of caspases (Hong, Dawson, Dawson, 2004; Malhi, Gores,
Lemasters, 2006; Jiang, Wang, 2004). Activation of caspases may result from a number of
potential mechanisms, but the end result of caspase activation is activation of apoptotic pathways
(McGill, Sharpe, Williams, Taha, Curry, Jaeschke, 2012; Gujral, Knight, Farhood, Bajt,
Jaeschke, 2002; Davidson and Eastham, 1966; Hong, Dawson, Dawson, 2004; Jaeschke, H.,
Cover, C., Bajt, M., 2006; Majno, Joris, 1995). ATP depletion results from a necrotic pathway. A
depletion of ATP stores results in cell swelling, where cell membranes eventually burst leading
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to cell death (Malhi, Gores, Lemasters, 2006; Majno, Joris, 1995; Goldblatt, Trump, Stowell,
1965; Nieminen, Gores, Wray, Tanaka, Herman, Lemasters, 1988; Herman, Nieminen, Gores,
Lemasters, 1988). Significant reductions to glutathione may also result from hepatotoxic events
such as the production of reactive oxygen species. Because glutathione works as an antioxidant
to repair damaged cells, reductions in levels may result in more widespread damage due to cells’
inability to prevent damage from reactive metabolites produced as a result of drug-induced
toxicity (Nýdlova, Vrbová, Česla, Jankovičová, Ventura, Roušar, 2013; McCluskey, Harbison,
Sava, Johnson, Harbison, 2012; Labib, Turkall, Abdel-Rahman, 2002; McCluskey, Sava,
Harbsion, Muro-Cacho, Johnson, Ping, Harbison, 2011; Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas,
Türker, Kaldirim, Korkmaz, 2015; Cover et al. 2005a; James, Mayeux, Hinson, 2003; McGill et
al. 2013; McGill, Sharpe, Williams, Taha, Curry, Jaeschke, 2012).

Cocaine and Hepatotoxicity
The liver is a known target of cocaine toxicity. The hepatic injury that may result from
cocaine overdose is likely to be extensive throughout many liver cells and tissue. Studies have
shown that whether the dose is acute or chronic, measured liver enzymes indicate that some level
of damage to the liver occurs from either frequency of administration of the drug (Mehanny,
Abdel-Rahman, 1991; Evans, Dwivedi, Harbison, 1977; Shuster, Freeman, and Harbison, 1977;
Freeman, Harbison, 1981; Devi, Chan, 1997). Hepatotoxicity resulting from acute cocaine doses
has been shown to be dependent upon the induction cytochrome P450 oxidative enzymes
(Mehanny, Abdel-Rahman, 1991; Thompson, Shuster, Shaw, 1979; Freeman, Harbison, 1978;
Labib, Turkall, Abdel-Rahman, 2002; Freeman, Harbison, 1981; Devi, Chan, 1997). It is through
this oxidative pathway that reactive oxygen species are produced (Labib, Turkall, Abdel14

Rahman, 2002; Aoki, Ohmori, Takimoto, Ota, Yoshida, 1997). The production of these reactive
species causes damage to a number of organelles within the cell, such as damage to the cell
membrane and malfunctioning of mitochondria (Labib, Turkall, Abdel-Rahman, 2002; Devi,
Chan, 1997; Ndikum-Moffor, Roberts, 2003). As a result glutathione levels are expected to be
reduced along with ATP stores within the cell. Depletion of ATP stores impact the cell’s ability
to withstand damage from ROS produced from cocaine toxicity (Labib, Turkall, Abdel-Rahman,
2002; Devi and Chan, 1996; Evans, 1983; Kovacic, 2004). These hepatotoxic events lead to a
defective cell that swells and eventually bursts. This damage eventually causes what has been
observed as necrotic damage to cells and tissues resulting from cocaine hepatotoxicity (Roth,
Harbison, James, Tobin, Roberts, 1992).
Research has shown that pretreatments may help to reduce the extent of liver damage that
results from cocaine hepatotoxic events. Studies evaluated the effectiveness of pretreatments on
both acute and chronic cocaine drug treatments (Labib, Turkall, Abdel-Rahman, 2002;
McCluskey, Harbison, Sava, Johnson, Harbison, 2012; McCluskey, Sava, Harbison, MuroCacho, Johnson, Ping, Harbison, 2011). The purpose is to reduce ALT levels, restore ATP, and
increase the production of glutathione. Research has shown that improvements of these elements
have significant impacts on reducing widespread liver damage, and in some cases, may also
reverse observed damage from cocaine-induced hepatotoxicity (McCluskey, Harbison, Sava,
Johnson, Harbison, 2012; Ozer, Ratner, Shaw, Bailey, Schomaker, 2007). However, the key to
altering the toxicity produced by reactive oxygen species is to protect the cell membrane and
mitochondria to maintain viable cells that can increase glutathione production that will aid in the
reduction of toxic cocaine metabolites (Donnelly, Boyer, Petersen, Ross, 1988; McCluskey,
Harbison, Sava, Johnson, Harbison, 2012).
15

Acetaminophen and Hepatotoxicity
Acetaminophen hepatotoxicity may result from drug-induced liver injury that may cause
permanent damage to liver cells and tissue (Enomoto, Itoh, Nagayoshi, Haruta, Kimura,
O’Connor, Harada, Yamamoto, 2001; Ingawale, Mandlik, Naik, 2014; Brodie, Reid, Cho, Sipes,
Krishna, Gillette, 1971; Mitchell, Jollow, Potter, Davis, Gillette, Brodie, 1973; Reid, Krishna,
Mitchell, Moskowitz, Brodie, 1971; Cover et al, 2005a; James, Mayeux, Hinson, 2003; Dӧnmez,
Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015). Hepatotoxic events develop
from the production of the toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), by
cytochrome p450 enzymes. The production of NAPQI depletes glutathione and binds to the
amino acid cysteine within the cell (McGill, Williams, Xie, Ramachandran, Jaeschke, 2012;
Nelson, 1990; James, Mayeux, Hinson, 2003; Cohen, Pumford, Khairallah, Boekelheide, Pohl,
Amouzadeh, Hinson, 1997; Nýdlova, Vrbová, Česla, Jankovičová, Ventura, Roušar, 2013). This
process stimulates the toxic events of oxidative stress resulting from damage caused by reactive
oxygen species to various parts of the cell (McGill, Williams, Xie, Ramachandran, Jaeschke,
2012; Kon, Kim, Jaeschke, Lemasters, 2004; Jaeschke, H., McGill, M., Ramachandran, A.,
2012; Cohen, Pumford, Khairallah, Boekelheide, Pohl, Amouzadeh, Hinson, 1997; Cover et al.,
2005b).
Exposures to toxic doses of acetaminophen may cause widespread mitochondrial damage
(McGill, Sharpe, Williams, Taha, Curry, S., Jaeschke, 2012; Jaeschke, H., McGill, M.,
Ramachandran, A., 2012). This mitochondrial dysfunction impacts the cytochrome p450 protein
mechanism. The mitochondrial damage to cytochrome p450 can lead to oxidative stress, which
may result in a production of free radicals (Park, Smith, Combs, Kehrer, 1988; Jaeschke, Gujral,
Bajt, 2004; Yoon, Kim, Lee, Chung, Kim, 2006; Jaeschke, Cover, Bajt, 2006; McGill, Williams,
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Xie, Ramachandran, Jaeschke, 2012; Cover et al., 2005b). These free radicals cause DNA
fragmentation that can serve as a precursor to necrotic cell death and injuries to liver tissue
(Cover et al., 2005a; McGill, Sharpe, Williams, Taha, Curry, Jaeschke, 2012; Williams, Koerner,
Lampe, Farhood, Jaeschke, 2011; James, Mayeux, Hinson, 2003; Kröger, Ehrlich, Klewer,
Grӓtz, Dietrich, Miesel, 1996; Jaeschke, McGill, Williams, Ramachandran, 2011).
Pretreatments have also been shown to improve hepatotoxic events resulting from
acetaminophen-induced toxicity (Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim,
Korkmaz, 2015; Ray, Kamendulis, Gurule, Yorkin, Corcoran, 1993). Administered
pretreatments aid in the reduction of elevations in ALT, and improve glutathione and ATP stores
that result from acetaminophen-induced hepatotoxic events. Reducing the production of the toxic
metabolite, NAPQI, will result in the improvement of glutathione stores that will improve
cellular function (Shi et al., 2012; Fernandes et al., 2011; Purnell, Whish, 1980; Dӧnmez, Uysal,
Poyrazoglu, Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015). Improving the damage that results
from hepatotoxic events may help to prevent widespread liver damage and reverse damage to
liver cells and tissue (Shi et al., 2012; Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim,
Korkmaz, 2015; Fernandes et al., 2011; Purnell, Whish, 1980).

Poly(ADP-ribose) Polymerase (PARP)
The role of cellular death in drug-induced toxicity has been studied for a number of
decades. While it is understood that the metabolic production of toxic metabolites contributes to
the damage in major cell organelles, the intermediate mechanistic pathways and contributors
continues to be debated (Cover et al., 2005b; Wang, Dawson, Dawson, 2009; James, Mayeux,
Hinson, 2003; Virág, Robaszkiewicz, Rodriguez-Vargas, Oliver, 2013). Damage to DNA is
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considered to be the main cellular response that results from the toxic events (Hong, Dawson,
Dawson, 2004). Resultant nicks and tears to single and double stranded DNA triggers a cellular
response to activate the enzyme poly(ADP-ribose) polymerase (PARP) by catalyzing modified
nuclear proteins via poly-ADP ribosylation (Wang, Dawson, Dawson. 2009; Cover et al., 2005b;
Scobie et al., 2014; Bouchard, Rouleau, Poirier, 2003; Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas,
Türker, Kaldirim, Korkmaz, 2015; Virág, 2005). PARP is a 116 kDa protein containing 3 main
domains: an N-terminal DNA-binding domain (42 kDa), a central automodification domain (16
kDa), and a C-terminal domain (55kDa). The N-terminal DNA-binding domain contains two
zinc fingers that aid recognizing nicks and tears to DNA strands (Hong, Dawson, Dawson, 2004;
Wang, Dawson, Dawson. 2009; Cover et al. 2005a; Bouchard, Rouleau, Poirier, 2003). (See
Figure 3.)
In the presence of drug and chemical-induced toxicity, an overproduction of PARP is
activated to compensate for the loss of cellular energy resulting from mitochondria dysfunction
and rapid depletion of NAD+ and ATP stores (McCluskey, Sava, Harbison, Muro-Cacho,
Johnson, Ping, Harbsion, 2011; Cover et al., 2005a; Scobie et al., 2014; Dӧnmez, Uysal,
Poyrazoglu, Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015; Virág, Robaszkiewicz, RodriguezVargas, Oliver, 2013; Aredia, Scovassi, 2014). Excessive activation of this PARP enzyme
depletes nicotinamide adenine dinucleotide (NAD+) within the cell. This depletion in NAD+
triggers a rapid depletion of adenosine triphosphate (ATP) within the cell. Rapid catabolism of
NAD+ impacts energy metabolism by causing mitochondrial dysfunction and decreases function
of the nucleus which eventually leads to cell death (Hong, Dawson, Dawson, 2004; McCluskey,
Harbison, Sava, Johnson, Harbison, 2012; McCluskey, Sava, Harbison, Muro-Cacho, Johnson,
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Figure 3. PARP Structure. A PARP structure containing the three main domains and two zinc
fingers (Bouchard, Rouleau, Poirier, 2003; Hong, Dawson, Dawson, 2004).

Ping, Harbsion, 2011; Bouchard, Rouleau, Poirier, 2003). The cell death that results is triggered
from the activation of one of the two common cellular death pathways: apoptosis or necrosis
(McCluskey, Harbison, Sava, Johnson, Harbison, 2012; Wang, Dawson, Dawson. 2009;
Bouchard, Rouleau, Poirier, 2003; Ha & Snyder, 1999; Virág, Robaszkiewicz, RodriguezVargas, Oliver, 2013). (See Figure 4.) Biochemical changes resulting from apoptosis include a
cell’s lack of ability to repair damage to DNA. Apoptosis results from the activation and
cleavage of effector caspases: caspase 3, caspase 6, and caspase 7. Other cases where an
apoptotic pathway may be activated include mitochondrial dysfunction and other proteases or
profactors that may trigger activation of effector and effector caspase pathways. Activation
results in the shrinking of cells where the cell eventually commits what is known as “cell
suicide” or programed cell death. The alternative common cellular death pathway of necrosis
includes an inflammatory response. Resulting from an over-activation of PARP due to decreases
in cellular function, cells activating this pathway produce a breakdown of the cell membrane due
to swelling. Eventually cells burst resulting in widespread cell and tissue damage (Hong,
Dawson, Dawson, 2004; Wang, Dawson, Dawson. 2009; Bouchard, Rouleau, Poirier, 2003;
McCluskey, Harbison, Sava, Johnson, Harbison, 2012; Cover et al., 2005b; Dӧnmez, Uysal,
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Poyrazoglu, Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015; Ha & Snyder, 1999; Virág,
Robaszkiewicz, Rodriguez-Vargas, Oliver, 2013).

Figure 4. Cell Death Model. Model displaying the outcomes of cell death resulting from
activation of PARP (Bouchard, Rouleau, Poirier, 2003; Hong, Dawson, Dawson, 2004; Wang,
Dawson, Dawson, 2009).

Cocaine and PARP
Cocaine has been shown to be toxic to the liver and produce hepatotoxic events resulting
from an acute or chronic dose (McCluskey, Harbison, Sava, Johnson, Harbison, 2012; Scobie et
al., 2014; Price, Muro-Cacho, Harbison, 1999; Evans, 1983). While the mechanism for cocaineinduced hepatotoxicity is not fully understood, the production of the norcocaine metabolite from
cocaine metabolism via cytochrome-P450 enzymes has been shown to elicit cytototoxic events
causing damage to liver cells and tissues (McCluskey, Harbison, Sava, Johnson, Harbison, 2012;
Roth, Harbison, James, Tobin, Roberts, 1992; Mehanny, Abdel-Rahman, 1991; Thompson,
Shuster, Shaw, 1979; Stewart, Inaba, Lucassen, Kalow, 1979). What was once thought to
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potentially be an apoptotic cell death pathway caused by cocaine has now been shown to be a
necrotic cell death pathway. Toxic doses of cocaine has been shown to deplete ATP and NAD+
stores, along with causing mitochondrial dysfunction and damage to DNA (McCluskey,
Harbison, Sava, Johnson, Harbison, 2012; Thompson, Shuster, Shaw, 1979; Roth, Harbison,
James, Tobin, Roberts, 1992; Evans, 1983; Devi & Chan, 1997). These cellular events lead to the
activation of PARP in order to attempt to replenish depleted ATP and NAD+ stores. However, in
the presence of cocaine-induced hepatotoxicity, an overproduction of the PARP enzyme causes
widespread damage to liver cells and tissues as cellular and mitochondrial function is impaired.
Eventually, hepatocyte membranes are damaged by reactive oxygen species and the cell is no
longer able to repair itself. As cellular function diminishes, cells swell and burst causing
widespread necrotic cell death (McCluskey, Harbison, Sava, Johnson, Harbison, 2012; Kovacic,
2005; Aoki, Ohmori, Takimoto, Ota, Yoshida, 1997; Roth, Harbison, James, Tobin, Roberts,
1992; Devi & Chan, 1997; Evans, 1983).

Acetaminophen and PARP
Hepatotoxic events resulting from an acetaminophen overdose may result in a number
impacts to hepatocyte function. The resultant hepatotoxic events may be caused by either an
acute or chronic dose. Impacts to hepatocytes include depletion of ATP and glutathione (GSH),
mitochondrial dysfunction, and inflammation. These events cause tearing of DNA strands that
may become permanently damaged and lead to cell death (Dӧnmez, Uysal, Poyrazoglu, Er
Ӧztas, Türker, Kaldirim, Korkmaz, 2015; Cover, C., et al., 2005a; McGill, Sharpe, Williams,
Taha, Curry, Jaeschke, 2012; McGill et al., 2013; James, Mayeux, Hinson, 2003; Gujral, Knight,
farhood, Bajt, Jaeschke, 2002; McGill, Williams, Xie, Ramachandran, Jaeschke, 2012; Mitchell,
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Jollow, Potter, Davis, Gillette, Brodie, 1973). The damage to DNA may lead to activation of
poly(ADP-ribose) polymerases (PARP) in the nucleus of a cell. However, too much production
of PARP leads to bursting of cells and necrotic cell death (Ha, H., Snyder, S., 1999; Cover, C., et
al., 2005a; Gujral, Knight, farhood, Bajt, Jaeschke, 2002; McGill, Sharpe, Williams, Taha,
Curry, Jaeschke, 2012; Williams, Koerner, Lampe, Farhood, Jaeschke, 2011; McGill et al., 2013;
Mitchell, Jollow, Potter, Davis, Gillette, Brodie, 1973).

Poly(ADP-ribose) Polymerase (PARP) Inhibition
Due to the widespread damage resulting from the activation of PARP, inhibiting the
activity of PARP via treatments with an inhibitor has been studied for a number of drugs and
chemicals (McCluskey, Sava, Harbison, Muro-Cacho, Johnson, Ping, Harbison, 2011;
McCluskey, Harbison, Sava, Johnson, Harbison, 2012; Virág, Szabó, 2002; Virág, 2005;
Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015; Southan, Szabó, 2003;
Hall, Muro-Cacho, Abritis, Johnson, Harbison, 2009-2010; Banasik, Stedeford, Strosznajder,
Takehashi, Tanaka, Ueda, 2011; Shi et al., 2011). While treatments have varied tremendously
due to their impacts on the metabolism of the drug being studied, the efficacy of treatments has
provided a number of potential options to decrease cell and tissue damage throughout the body
(McCluskey, Sava, Harbison, Muro-Cacho, Johnson, Ping, Harbison, 2011; McCluskey,
Harbison, Sava, Johnson, Harbison, 2012 Virág, Szabó, 2002; Virág, 2005; Southan, Szabó,
2003; de la Lastra, Villegas, Sánchez-Fidalgo, 2007; Shi et al., 2011). PARP inhibitors have been
used to understand the role of inhibition on PARP activity, as well their role in cellular functions
and signaling. Because PARP inhibition target DNA and mitochondria, the ability for an
inhibitor to decrease the depletion of ATP and NAD+ while inhibiting necrosis or apoptosis can
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prove to be a key component in its ability to prevent drug-induced hepatotoxicity (Virág, Szabó,
2002; Virág, 2005; Cover et al., 2005a; Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim,
Korkmaz, 2015; Southan, Szabó, 2003; de la Lastra, Villegas, Sánchez-Fidalgo, 2007; Hall,
Muro-Cacho, Abritis, Johnson, Harbison, 2009-2010).
The use of water-soluble PARP inhibitors can be used to determine the role on PARP
activity without potential interferences from chemical reactions and impacts on results gathered
from biochemical assays (McCluskey, Sava, Harbison, Muro-Cacho, Johnson, Ping, Harbison,
2011; Thiermann, 2002; Cover et al., 2005a; Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker,
Kaldirim, Korkmaz, 2015). A common water soluble PARP inhibitor, 1,5-dihydroxyisoquinoline
(DIQ), has been found to decrease PARP activity with little to no effects on the metabolism of
drug or chemicals used for inducing hepatotoxicity (McCluskey, Harbison, Sava, Johnson,
Harbison, 2012). Along with their ability to cause less interference with enzymatic reactions,
water soluble PARP inhibitors such as DIQ have been effective in preventing hepatotoxic events
(McCluskey, Sava, Harbison, Muro-Cacho, Johnson, Ping, Harbison, 2011; McCluskey,
Harbison, Sava, Johnson, Harbison, 2012; Cover et al., 2005a; Thiermann, 2002).

Objective

To determine if cocaine and acetaminophen-induced toxicity leads to the activation
of the repair protein, poly(ADP-ribose) polymerase (PARP) in the liver. If activation of this
PARP protein occurs, can this PARP activity be inhibited by the PARP inhibitor 1,5dihydroxyisoquinoline (DIQ).
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Research Questions
Research Question 1:
Are dosing and temporal factors correlated with increases in serum liver enzyme levels?
Research Questions 2:
Is there a correlation between temporal factors and PARP activity?
Research Question 3:
Is an increase in PARP activity indicative of hepatic biochemical changes relevant to the
mechanism of drug-induced hepatotoxicity?
Research Question 4:
Does DIQ provide protection against PARP activity for drug-induced toxicity with cocaine and
acetaminophen?

Hypotheses
Research Question 1:
Dosing and temporal factors are correlated with increases in serum liver enzyme levels.
Research Question 2:
There is a correlation between temporal factors and PARP activity.
Research Question 3:
An increase in PARP activity contributes to the mechanism of drug-induced hepatotoxicity.
Research Question 4:
DIQ decreases PARP activity and drug-induced toxicity caused by cocaine and acetaminophen.
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CHAPTER THREE:
METHODS

Animals
Male, CD-1 mice (30 ± 5 g), age 8 weeks, were obtained from Charles River
Laboratories (Wilmington, Massachusetts). Animals were housed under controlled conditions
and exposed to a 12-hour light/dark cycle with free access to food and water. Animals were
housed 5 animals per cage and were allowed 7 days to acclimate prior to testing. All of the
experiments were conducted in accordance to the University of South Florida Institutional
Animal Care and Use Committee (IACUC) guidelines.

Treatments
Drugs were administered through intraperitoneal (IP) injection at a volume of 50μL/10g
of body weight. All solutions were prepared fresh prior to treatment. Cocaine hydrochloride
(cocaine) was obtained from Sigma-Aldrich (St. Louis, MO) and 4-Acetamidophenol, 98%,
(APAP) was obtained from Acros Organics (Morris Plains, NJ). The PARP inhibitor, 1,5dihydroxyisoquinoline (DIQ), was obtained from AdipoGen (San Diego, CA). The PARP
inhibitor was administered through intraperitoneal (IP) injection at a volume of 50μL/10g of
body weight (b/w). Cocaine, APAP, and DIQ were dissolved in warm 0.9% saline prior to
administration. Groups for comparison were treated with either (I) saline vehicle, (II) cocaine,
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(III) APAP, (IV) cocaine and DIQ, or (V) APAP and DIQ. The combined administration of
toxicant and inhibitor did not exceed the maximum allowed volume of 200μL/10g b/w. The
injection sites for toxicants and PARP inhibitor were administered distant to one another to avoid
chemical interaction.

Experimental Design
Animals were randomized into treatment groups as shown in Tables 1 through 8. Animals
were randomly assigned to control groups where the number of animals in each treatment group
was approximately double that of the number in the control groups. The number of animals in
each treatment group ranged from 4 to 8 depending on the size of the experiment.

Serum Biochemistry
Alanine aminotransferase (ALT), a biomarker of hepatotoxicity, was quantified in
triplicate using a colorimetric endpoint kit from TECO Diagnostics (Anaheim, CA) from the
modified method by Reitman et al. (Reitman & Frankel, 1957). Whole blood was collected by
cardiac puncture in microcentrifuge tubes and allowed to clot at room temperature for a
minimum of 20 minutes. Serum was obtained from each individual sample by centrifugation at 6
rcf for 20 minutes. Serum samples were transferred to a new microcentrifuge tube and stored at 20°C until time of assay. All serum samples were analyzed within a 24 hour period. Serum
samples were diluted with 0.9% saline for assay calculations. Standard curve was optimized for
high concentrations using sodium pyruvate from Sigma-Aldrich (St. Louis, MO). Regents (ALT
(SGPT) substrate, ALT (SGPT) color reagent, and ALT (SGPT) calibrator) were transferred to
microplate with diluted samples at timed intervals, immediately followed by heat incubation at
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37°C for specified time increments. Assay sample processing was modified in order to analyze
samples using a 96-well assay plate. Assay plates were read by a spectrophotometer at 505 nm.
Results are presented as total international units of ALT per serum sample. Modifications were
made to calibration calculations using sodium pyruvate due to excessive levels of ALT measured
among samples.

Dose-Response Analysis
To determine the optimal dose for cocaine and APAP-induced hepatotoxicity, a doseresponse study was conducted. Animals were sacrificed 24 hours after treatment. Animals treated
with cocaine were administered (1) Vehicle only, (2) 20 mg/kg dose, (3) 30 mg/kg dose, (4) 40
mg/kg dose, (5) 50 mg/kg dose, or (6) 60 mg/kg dose. (See Table 1.) Animals treated with APAP
were administered (1) Vehicle only, (2) 75 mg/kg dose, (3) 150 mg/kg dose, (4) 200 mg/kg dose,
or (5) 300 mg/kg dose. (See Table 2.) Blood samples were collected by cardiac puncture to
determine alanine transaminase (ALT).

Table 1. Dose-Response for Cocaine.
Treatment Group
Group I
Group II
Group II
Group II
Group II
Group II

Chemicals
Vehicle Only
Cocaine
Cocaine
Cocaine
Cocaine
Cocaine

Dose
0 mg/kg
20 mg/kg
30 mg/kg
40 mg/kg
50 mg/kg
60 mg/kg

Temporal Analysis
To determine the optimal time for cocaine and APAP-induced heptatotoxicity, a time study was
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conducted. Animals were administered a (II) 50 mg/kg dose of cocaine or a (III) 300 mg/kg dose
of APAP. Animals were sacrificed at a 2 hour, 6 hour, 18 hour, or 24 hour time point following
treatment (See Tables 3 & 4.) Blood samples were collected by cardiac puncture to determine
alanine transaminase (ALT).

Table 2. Dose-Response for APAP.
Treatment Group
Group I
Group III
Group III
Group III
Group III

Chemicals
Vehicle Only
APAP
APAP
APAP
APAP

Dose
0 mg/kg
75 mg/kg
150 mg/kg
200 mg/kg
300 mg/kg

Table 3. Temporal Analysis for Cocaine.
Treatment Group
Group I

Chemicals
Vehicle Only

Dose
0 mg/kg

Group II
Group II
Group II
Group II

Cocaine
Cocaine
Cocaine
Cocaine

50 mg/kg
50 mg/kg
50 mg/kg
50 mg/kg

Time
2 hr, 6 hr, 18 hr, 24
hr
2 hr
6 hr
18 hr
24 hr

Table 4. Temporal Analysis for APAP.
Treatment Group
Group I

Chemicals
Vehicle Only

Dose
0 mg/kg

Group III
Group III
Group III
Group III

APAP
APAP
APAP
APAP

300 mg/kg
300 mg/kg
300 mg/kg
300 mg/kg

Time
2 hr, 6 hr, 18 hr, 24
hr
2 hr
6 hr
18 hr
24 hr

Poly(ADP-ribose) Polymerase (PARP) Activity
An indirect colorimetric method to measure poly(ADP-ribose) polymerase (PARP) was
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used to measure the activity of PARP in liver tissue following cocaine or APAP treatments. (See
Tables 5 & 6.) Livers were isolated and perfused with normal saline, and stored at -80◦C until
used for assay. PARP activity was measured using an 80 ± 10 mg sample of liver tissue
homogenized with a mortar and pestle, sonicated at a medium setting, and centrifuged at 0.6 rcf
for 5 minutes in a 1X lysis buffer (Triton X-100, D-l-1,4-dithiothreitol (DTT), double distilled
water (ddH2O), sodium chloride (NaCl), and 10X PARP Buffer (Tris base, magnesium chloride
(MgCl2•6H2O), bovine serum albumin (BSA), 1.78M hydrochloric acid (HCl), and ddH2O) to
remove excess proteins. A transfer of supernatant to a new tube was centrifuged at 4.0 rcf for 10
minutes. After 10 minutes the supernatant is discarded and the nuclear fraction remains. The1X
PARP buffer was added to the nuclear fraction for each sample, with the addition of glycerol,
and was stored at -80◦C in order to prevent degradation of proteins. Protein concentration
quantification was determined utilizing the biuret method for a bicinchoninic acid (BCA) assay
prior to PARP activity measurements for sample loading. Samples were diluted with saline and
working reagents A and B were combined and added to change protein samples from green to
purple during a 30 minute incubation at 37°C. (See Figure 5.) Concentrations of protein were
calculated for 20μg of protein/well and diluted with 1X PARP buffer on Day 3 of PARP activity
measurement. PARP activity measurement consisted of a three day process using an enzymelinked immunosorbent assay (ELISA) microplate, (Day 1) plating of histones, (Day 2) blocking
step, (Day 3) PARP activity detection. Day 1 consisted of preparing a histone coating solution
consisting of sodium carbonate (Na2CO3), sodium bicarbonate (NaHCO3), stock histone solution
(Fraction V Histones), and ddH2O, and coating each well of a 96-well plate with histone coating
solution. Day 2 consisted of a blocking step that began with a washing step with phosphatebuffered saline (PBS) of the 96-well ELISA microplate with 1X PBS and 1X PBS + 0.05%
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Tween-20. Washing steps were followed by the addition of a 3% BSA blocking solution to each
well. After Day 1 and Day 2 procedure was conducted, microplate was stored at -20◦C. Day 3
consisted of measurement of PARP activity where sample dilutions were calculated from protein
quantification conducted prior to Day 3 assay. PARP-High Specific Activity Enzyme (HSA) was
used to create calibration curve. Assay processing begins with a 1X PBS and 1X PBS + 0.05%
Tween-20 washing step, followed by the addition of samples diluted with 1X PARP buffer to the
96-well ELISA microplate. Reagents used on Day 3 consists of 1X PARP substrate (6-biotin-17nicotinamide-adenine-dinucleotide (NADB), sheared herring sperm DNA, 10X PARP buffer, and
ddH2O) (1 hour incubation at room temperature), 1:60,000 streptavidin-conjugated horseradish
peroxidase (streptavidin-HRP)) (1 hour incubation at room temperature), 3,3’,5,5’tetramethylbenzidine (TMB) (20 minute incubation at room temperature), and 0.2M HCl (10
minute incubation at room temperature). After the addition of each reagent to the 96-well ELISA
microplate a washing step is conducted with 1X PBS and 1X PBS + 0.05% Tween-20. The
microplate was read at 450 nm using an ELISA microplate reader at the end of the Day 3
procedure. (See Figure 6.) A standard curve using a fitted regression model was used to quantify
samples. PARP activity was reported as IU per 20 μg of protein per well.

Table 5. PARP Activity for Cocaine.
Treatment Group
Group I

Chemicals
Vehicle Only

Dose
0 mg/kg

Group II
Group II
Group II
Group II

Cocaine
Cocaine
Cocaine
Cocaine

50 mg/kg
50 mg/kg
50 mg/kg
50 mg/kg
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Time
2 hr, 6 hr, 18 hr, 24
hr
2 hr
6 hr
18 hr
24 hr

Table 6. PARP Activity for APAP.
Treatment Group
Group I
Group III
Group III
Group III
Group III

Chemicals
Vehicle Only
APAP
APAP
APAP
APAP

Dose
0 mg/kg
300 mg/kg
300 mg/kg
300 mg/kg
300 mg/kg

Time
2 hr, 6 hr, 18 hr, 24 hr
2 hr
6 hr
18 hr
24 hr

Figure 5. Protein Quantification. A endpoint colorimetric bicinchoninic acid (BCA) assay used
to quantify the concentration of protein used for PARP activity analysis.

Figure 6. PARP Activity. A resultant PARP analysis assay with a 96-well microplate for an
endpoint colorimetric assay measured by spectrophotometry.
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Poly(ADP-ribose) Polymerase (PARP) Inhibition
An inhibitory efficacy study was conducted to determine if a PARP inhibitor, DIQ
(AdipoGen), reduced ALT and PARP activity. A 10 mg/kg dose of DIQ was dissolved in warm
saline and administered via IP injection at the time points of 0 hour, concurrent with treatment
dose, or 1 hour after treatment dose. PARP inhibition analyses were conducted at time points
where PARP activity was highest to measure any reductions in PARP activity that occurred
following cocaine and APAP treatment. (See Tables 7 & 8.) Cocaine PARP inhibition analyses
were conducted at the 6 hour time point. APAP PARP inhibition analyses were conducted at the
18 hour time point. The effect of DIQ on PARP inhibition was also analyzed along with
glutathione (GSH), DNA fragmentation, and Western Blot.

Table 7. PARP Inhibition: Activity, ALT, GSH, DNA Fragmentation, and Western Blot for
Cocaine + DIQ at the 6 hour Time Point.
Treatment Group
Group I
Group II
Group IV
Group IV

Chemicals
Vehicle Only
Cocaine Only
Cocaine + DIQ
Cocaine + DIQ

Dose
0 mg/kg
50 mg/kg
50 mg/kg + 10 mg/kg
50 mg/kg + 10 mg/kg

Time
0 hr, 1 hr
0 hr, 1 hr
0 hr
1 hr

Table 8. PARP Inhibition: Activity, ALT, GSH, DNA Fragmentation, and Western Blot for
APAP + DIQ at the 18 hour Time Point.
Treatment Group
Group I
Group III
Group V

Chemicals
Vehicle Only
APAP Only
APAP + DIQ

Group V

APAP + DIQ

Dose
0 mg/kg
300 mg/kg
300 mg/kg + 10
mg/kg
300 mg/kg + 10
mg/kg
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Time
0 hr, 1 hr
0 hr, 1 hr
0 hr
1 hr

Glutathione
An analysis was conducted to determine the role of glutathione (GSH) on PARP activity.
A modified colorimetric kinetic glutathione assay measured the ratio of the reduced form of
glutathione to its oxidized form by Griffith and Rahman et al (Griffith, 1980; Rahman, Kode, &
Biswas, 2006). Livers were isolated and perfused with normal saline, and stored at -80◦C until
needed for assay. Prior to assay a 30 ± 10 mg sample of liver tissue was homogenized with a
mortar and pestle on ice and centrifuged at 4.0 rcf for 10 minutes in a GSH extraction reagent
(metaphosphoric acid (MPA), 5-sulfosalicylic acid, and double distilled water (ddH2O). The
homogenized tissue for each sample was stored at -80◦C in order to prevent degradation. Aliquot
samples were transferred into two tubes for measurement of total glutathione and oxidized
glutathione. Samples were analyzed utilizing a 96-well microplate. Standards and samples were
diluted with KPE buffer (0.1 M KH2PO4, 97.6 mM K2HPO4, Na2EDTA, and ddH2O) prior to
assay. Reagents for assay include 0.066% w/v Ellman’s Reagent (DTNB), 0.066% w/v βNADPH, and glutathione reductase (10 Units/mL), working substrate reagent (1:1
DTNB:glutathione reductase), 2-vinylpyridine working reagent, and triethanolamine working
reagent. Total glutathione procedures were conducted first, followed by oxidized glutathione.
The microplate was read five times at 412 nm using a microplate reader at the end of each
procedure. Oxidized glutathione is calculated from total glutathione to compute a reduced to
oxidized glutathione ratio.

DNA Fragmentation
A DNA fragmentation analysis using a modified Herrmann et al. method was conducted
to determine if fragmented DNA results from hepatotoxic events with cocaine and APAP
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overdose (Hermann, Lorenz, Voll, Grünke, Woith, and Kalden, 1994). DNA fragmentation
analyses were conducted with cocaine, APAP, cocaine + DIQ, and APAP + DIQ samples with
1.6% agarose gel. (See Figure 7.) The two day assay procedure consisted of tissue preparation
(Day 1) and DNA analysis (Day 2). Livers were isolated and perfused with normal saline, and
stored at -80◦C until needed for assay. Day 1 consisted of tissue preparation of a 20 ± 10 mg
sample of liver tissue saturated in a LB9.0 buffer (1M Tris base, 500mM
ethylenediaminetetraacetic acid (EDTA), 4M sodium chloride (NaCl), 10% sodium dodecyl
sulfate (SDS), 1M sodium hydroxide (NaOH), 10 mg/mL proteinase K, autoclaved ddH2O) and
placed on a heating block/dry bath to dissolve for at least 12 hours. Day 2 of assay included
addition of the reagents RNAse, 4M sodium acetate, and 70% ethanol. Samples were place in a
centrifuge for 10 minutes at 14 rcf. Samples were incubated for 1 hour at -20°C. After 1 hour, a
small volume of each sample was transferred to a new microcentrifuge tube and XCog (10 mM
Tris base, 12 mM EDTA, 50% v/v Glycerol, 0.03% w/v Xylene Cyanol, 0.15% w/v Orange G,
and HCl) was added to each sample before samples were added to wells. A resuspension buffer
(3 mM Tris base, 0.2 mM EDTA, and HCl) was used as a loading control. A 1.6% agarose gel
with ethidium bromide was used to run DNA samples in a 1X TAE buffer solution (SigmaAldrich) at 75V for 2 hours. After 2 hours, gel was placed on UV light and photos were taken.

Western Blot
A western blot analysis was conducted to identify PARP protein sequences in liver
tissues for a 50 mg/kg dose of cocaine at the 6 hour time point and a 300 mg/kg dose of APAP at
the 18 hour time point. Livers were isolated and perfused with normal saline, and stored at -80◦C
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Figure 7. DNA Fragmentation Electrophoresis Gel. An electrophoresis gel used to analyze
treatment samples for fragmented DNA.

until needed for assay. Prior to assay a 10 ± 10 mg sample of liver tissue was homogenized with
a mortar and pestle on ice and centrifuged at 14.0 rcf for 5 minutes in a
radioimmunoprecipitation assay (RIPA) buffer (1M Tris base, 500mM
ethylenediaminetetraacetic acid (EDTA), 4M sodium chloride (NaCl), 10% sodium dodecyl
sulfate (SDS), Triton X-100, 1.78M HCl, deoxycholic acid, and autoclaved ddH2O). After
centrifugation, sample lysate was stored at -80°C until time of assay to prevent degradation of
proteins. Protein concentration quantification was determined utilizing the biuret method for a
BCA assay prior to western blot analysis. Samples were diluted with saline and working reagents
A and B were combined and added to change protein samples from green to purple during a 30
minute incubation at 37°C. Concentrations of protein were calculated for 10-15U of protein/well
and diluted with saline and Laemmli sample buffer prior to assay. Diluted samples + Laemmli
sample buffer were loaded on a 4-10.5% Tris-glycine polyacrylamide gel for electrophoresis at
12V. Proteins were transferred to nitrocellulose membranes, which were incubated in 3% BSA
blocking buffer (30 minute incubation at room temperature), 1:10,000 primary antibodies (one
hour incubation at room temperature), 1:50,000 secondary antibodies (1 hour incubation at room
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temperature), and streptavidin-HRP (25 minutes at room temperature). After the addition of each
reagent, membranes were washed with Tris-buffered saline + 0.1% Tween-20 (TBS-T).
Resultant nitrocellulose and gels were quantified using a Thermo Scientific PageRuler Unstained
Protein Ladder (10 to 200 kDa). (See Figure 8.) The molecular weight for PARP measures at 116
kDa (Boulares et al. 1999; Hong, Dawson, Dawson, 2004).

Figure 8. Western Blot Protein Ladder. A protein ladder display used to measure the molecular
weight for PARP at 116 kDa.

Gross Pathology
Livers were isolated and partially perfused with normal saline following necropsy of each
animal. Visual findings were recorded to correlate with ALT and PARP activity. Photographs
were taken at the 24 hour time point for a 50 mg/kg dose of cocaine, a 300 mg/kg dose of APAP,
and controls.

Spectrophotometry
Assays requiring colorimetric endpoint measurements (ALT, PARP, PARP Inhibition,
and GSH) were quantified using the μQuant Spectrophotometer (BioTek, Winooski, VT) with
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the KC-Junior Analytical software (BioTek). (See Figure 9.) Each colorimetric endpoint was
assessed at the wavelength stated within the assay section above.

Figure 9. μQuant Spectrophotometer. The spectrophotometer used to read microplates and
quantify biochemical medium as the amount of absorbed light that is proportionate to the
concentration of the measured solution.

Statistical Analysis
Statistical analysis was performed utilizing Microsoft Excel and the software program,
SAS version 9.3. A one-way analysis of variance (ANOVA) test was performed to test
comparisons among groups. Comparisons between treatment groups were conducted with
independent sample t-tests. Statistical differences were considered significant with p ≤ 0.05.
Adjustments for multiple comparisons were conducted utilizing a Tukey test.
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CHAPTER FOUR:
RESULTS

Dose-Response
A dose-response analysis was conducted for cocaine and acetaminophen (APAP) to
determine the optimal dose that produces hepatotoxic events. A single dose of cocaine or APAP
was administered via intraperotineal (IP) injections (n=6) and evaluated animals 24 hours after
treatment. A measurement of the alanine aminotransferase (ALT) was chosen to analyze the
severity of liver damage that resulted from drug toxicity. The determined optimal dose for both
toxicants was used to analyze poly(ADP-ribose) polymerase (PARP) activity.
Serum ALT (IU/L) measurements were conducted for a 20 mg/kg, 30 mg/kg, 40 mg/kg,
and 50 mg/kg, and 60 mg/kg dosages of cocaine at 24 hours following treatment. (See Figure
10.) Elevated serum ALT levels were measured for each dose. ALT increased incrementally for
the 20, 30, 40, and 50 mg/kg dosages. ALT for the control group ranged from 30-40 IU/L. The
highest ALT level of 1749 IU/L was observed at the 50 mg/kg dose group. A decreased level of
1362 IU/L was observed with the 60 mg/kg dose. The 60 mg/kg dose resulted in severe
hemorrhaging that caused a decrease in the amount of drug metabolized by the liver. This
resulted in a decrease in ALT levels observed from the 50 to 60 mg/kg dose groups. Each dose
group was statistically significantly increased at a (p ˂ 0.05) significance level when compared
to controls.
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Figure 10. Cocaine Dose-Response Analysis. A dose response analysis was conducted for a 20
mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg dose, and 60 mg/kg dose of cocaine at 24 hours following
treatment (n=6). Mean serum ALT levels with standard deviations are denoted with error bars.
An (*) denotes statistical significance at (p ˂ 0.05) when compared to controls.

Serum ALT measurements were also conducted for 75 mg/kg, 150 mg/kg, 200 mg/kg,
and 300 mg/kg doses of acetaminophen (APAP) at 24 hours following treatment (See Figure 11.)
ALT for the control group ranged from 30-40 IU/L. Each dose group resulted in elevations in
ALT. Serum ALT levels for the 75 mg/kg (45 IU/L) and 150 mg/kg (316 IU/L) dose groups did
not result in significant elevations of ALT. A 200 mg/kg dose of APAP resulted in a significant
increase in serum ALT of 2252 IU/L. Higher serum measurements in ALT were observed with
the 200 mg/kg and 300 mg/kg dose groups. The highest observed serum ALT was measured
with the 300 mg/kg dose group at 4311 IU/L. Each dose group was statistically significant at a (p
˂ 0.05) significance level when compared to controls.
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Figure 11. APAP Dose-Response Analysis. A dose-response analysis comparing serum ALT
was conducted for a 75 mg/kg, 150 mg/kg, 200 mg/kg, and 300 mg/kg dose of acetaminophen
(APAP) at 24 hours following treatment(n=6). Standard deviations are denoted with error bars.
An (*) denotes statistical significance at (p ˂ 0.05) when compared to controls.

Temporal Analysis
A temporal analysis was conducted for cocaine and acetaminophen (APAP) to determine
the optimal time to measure PARP activity. A single dose of cocaine or APAP was administered
via intraperotineal (IP) injection (n=6) where serum and livers were harvested at 2 hour, 6 hour,
18 hour, and 24 hour time points. A measurement of serum ALT (IU/L) was chosen to analyze
the severity of liver damage that resulted from drug-induced toxicity at each time point. The
optimal time point for both toxicants was based on the observed serum ALT levels following
drug treatment to analyze poly(ADP-ribose) polymerase (PARP) activity.
A 50 mg/kg dose of cocaine was determined to be the optimal dose that produced
hepatotoxicity but did not cause death. This 50/kg dose of cocaine was used to conduct a
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temporal analysis of serum ALT levels over a 24 hour period. ALT levels were conducted at a 2
hour, 6 hour, 18 hour, and 24 hour time point following treatment. (See Figure 12.) Serum ALT
for the control group ranged from 30-40 IU/L. Serum ALT levels were measured at each time
point. An initial increase in ALT at the 2 hour following treatment time point was measured at
450 IU/L. A significant increase in serum ALT was observed from the 2 to 6 hour time point
following treatment with a measurement of 1847 IU/L observed at the 6 hour time point. Serum
ALT increased incrementally during the 6, 18, and 24 hour time points following treatment. The
highest observed serum ALT level of 3231 IU/L was observed at the 24 hour time point. Serum
ALT measurements at the 6 hour, 18 hour, and 24 hour time points were statistically significant
at a (p ˂ 0.05) significance level when compared to controls.
Liver samples from a saline control and a 50 mg/kg dose of cocaine were collected at a
24 hour time point following treatment. (See Figure 13.) When compared to the control liver
sample, the cocaine liver appears smaller in size, including abnormal shapes of the lobes of the
liver sample. Some hemorrhaging and necrosis appears on the surface of the liver. Motteling on
the surface of the liver was also observed at the 24 hour time point when compared to controls.
Serum ALT measurements were conducted at a 2 hour, 6 hour, 18 hour, and 24 hour time
point following APAP treatments. (See Figure 14.) Serum ALT for the control group ranged
from 30-40 IU/L. Elevated ALT levels were measured for each time point. A significant increase
in ALT was observed at the 2 hour time point with a measurement of 1507 IU/L. ALT increased
incrementally at each time point. The highest observed serum ALT of 4994 IU/L was observed at
the 24 hour time point. ALT measurements at the 2 hour, 6 hour, 18 hour, and 24 hour time
points were statistically significant at a (p ˂ 0.05) significance level when compared to controls.
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Figure 12. Cocaine Temporal Analysis. A temporal analysis for a 50 mg/kg dose of cocaine was
conducted at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatment (n=6).
Standard deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂
0.05) when compared to controls.

Liver samples from a saline control and a 300 mg/kg dose of APAP treated animal were
collected at 24 hours following treatment. (See Figure 15.) When compared to the control liver
sample, lobes of the liver appear smaller in size when compared to controls. Significant
hemorrhaging and necrosis appears throughout the liver. Slight discoloration is observed on the
outer edges of the APAP liver sample.
A comparison of serum ALT for a 50 mg/kg dose of cocaine and a 300 mg/kg dose of
APAP at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatment. (See Figure 16.)
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Figure 13. Gross Pathology: Control + 50 mg/kg Cocaine. Liver samples were harvested for a
saline control (left) and a 50 mg/kg dose of cocaine (right) at 24 hours following treatment.

ALT increased at a much faster rate following APAP treatment compared to cocaine. A
significant increase in serum ALT following cocaine treatment was observed at the 2 and 6 hour
time point. A significant increase was observed at the 18 hour and 24 hour time points for both
toxicants following treatments.
The line graph comparison for cocaine and APAP-induced serum ALT changes at a 2
hour, 6 hour, 18 hour, and 24 hour time points following treatments shows a steady increase in
ALT for APAP from the 2 hour to 24 hour time point when compared to controls. (See Figure
17.) The graph also shows a steady increase from the 2 hour to 18 hour time point for cocaine. A
much smaller increase was observed for cocaine from the 18 hour to 24 hour time points when
compared to controls.
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Figure 14. APAP Temporal Analysis. A temporal analysis for a 300 mg/kg dose of APAP was
conducted at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatment (n=6).
Standard deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂
0.05) when compared to controls.

Poly(ADP-Ribose) Polymerase (PARP) Activity

A 50 mg/kg dose of cocaine and a 300 mg/kg dose of acetaminophen (APAP) were
determined to be the optimal dose to analyze PARP activity. This optimal dose for cocaine and
APAP was used to conduct a PARP activity analysis over a 24 hour period. PARP activity
(IU/20 μg of protein) was measured at a 2 hour, 6 hour, 18 hour, and 24 hour time point
following cocaine and APAP treatments. An ALT and PARP activity analysis was conducted for
both cocaine and APAP-induced heptotoxicity.
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Figure 15. Gross Pathology: Liver samples were harvested for a saline control (left) and a 300
mg/kg APAP dose (right) at 24 hours following treatment.

PARP activity was measured at a 2 hour, 6 hour, 18 hour, and 24 hour time point
following treatment with a 50 mg/kg dose of cocaine. (See Figure 18.) Activation of PARP
activity was measured at each time point. Elevations in PARP activity were measured for each
time point. PARP activity for the control measured at 0.2 IU/20 μg of protein. Cocaine increased
PARP activity at the 2 hour time point following treatment. The highest activity was 1.43 IU/20
μg of protein was measured at the 6 hour time point. An increase in activity was also measured
from the 2 to 6 hour time point. A decrease in PARP activity was also observed from the 6 to 18
hour time point but remained significantly increased above controls. The lowest amount of
PARP activity was measured at the 24 hour time point at 1.04 IU/20 μg of protein. PARP
activity measurements at the 2 hour, 6 hour, 18 hour, and 24 hour time points were statistically
significantly elevated at a (p ˂ 0.05) significance level when compared to controls.
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Figure 16. Cocaine and APAP Temporal Analysis: Bar Chart. A bar chart comparison of the
serum ALT temporal differences between a 50 mg/kg dose of cocaine and a 300 mg/kg dose of
APAP at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatments (n=6). Standard
deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂ 0.05) when
compared to controls.

PARP activity increased in liver tissue at a 2 hour, 6 hour, 18 hour, and 24 hour time
point following a 50 mg/kg dose of cocaine. (See Figure 19) A seven fold increase for PARP
activity shows that the largest increase in PARP activity was observed at the 6 hour time point
when compared to controls. Lower increases were observed at the 18 and 24 hour time points.
The smallest increase was observed at the 24 hour time point with a 5.60 increase measured.
PARP activity was measured at 2 hour, 6 hour, 18 hour, and 24 hour time point for a 300
mg/kg dose of APAP. (See Figure 20.) An activation of PARP activity was measured at each
time point. Elevations in PARP activity were measured for each time point. PARP activity for
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Figure 17. Cocaine and Temporal Analysis: Line Graph. A line graph comparison of the
temporal analysis for serum ALT following a 50 mg/kg dose of cocaine and a 300 mg/kg dose of
APAP was conducted at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatment
(n=6).

the control was 0.23 IU/20 μg of protein. APAP increased PARP activity at the 2 hour and 6
hour time points. The highest activity of 1.55 IU/20 μg of protein was measured at the 18 hour
time point. A significant increase in activity was also measured at the 6 and 18 hour time points.
A decrease in PARP activity was observed at the 18 and 24 hour time points but remained above
the controls. The lowest amount of PARP activity was measured at the 24 hour time point at 1.23
IU/20 μg of protein. Increases in PARP activity at the 2 hour, 6 hour, 18 hour, and 24 hour time
points were statistically significant at a (p ˂ 0.05) significance level when compared to controls.
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Figure 18. PARP Activity for Cocaine. A PARP analysis of liver tissue following 50 mg/kg dose
of cocaine at 2 hour, 6 hour, 18 hour, and 24 hour time points following an initial dose (n=6).
Standard deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂
0.05) when compared to controls.

Increases in PARP activity were measured at the 2 hour, 6 hour, 18 hour, and 24 hour
time points following a 300 mg/kg dose of APAP. (See Figure 21.) The largest increase was
observed at the 18 hour time point with a measurement of 7.75. A lower level was observed at
the 24 hour time point. The smallest increase was observed at the 2 hour time point with a
measurement of a 2.50 fold increase.
A comparison of liver PARP activity following a 50 mg/kg dose of cocaine and a 300
mg/kg dose of APAP at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatments.
(See Figure 22.) A delayed elevation of PARP activity was observed following APAP treatment.
Cocaine-induced PARP activity showed significant increases at the earlier time points. PARP
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Figure 19. PARP Activity Fold Change for Cocaine. Increases in PARP activity following a 50
mg/kg dose of cocaine at 2 hour, 6 hour, 18 hour, and 24 hour time points following treatment
(n=6).

activity levels are higher at the 2 and 6 hour time points for cocaine when compared to APAP.
APAP-induced PARP activity levels are higher at the 18 and 24 hour time points. Cocaine and
APAP showed a decrease in PARP activity from the 18 to the 24 hour time point.
The line graph comparison of increase in PARP activity following a 50 mg/kg dose of
cocaine and a 300 mg/kg dose of APAP at 2 hour, 6 hour, 18 hour, and 24 hour time points
following treatment shows a significant difference in PARP activity over the observed 24 hour
period. (See Figure 23.) PARP activity was higher at early time points within the 24 hour
observation period for cocaine treatments. PARP activity had a slower rate of increase for APAP
treatments during the 24 hour observation period. APAP-induced PARP activity was higher
following cocaine treatments during the 24 hour observation period.
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Figure 20. PARP Activity for APAP. A PARP activity for liver samples for a 300 mg/kg dose of
APAP at a 2 hour, 6 hour, 18 hour, and 24 hour time points following treatment (n=6). Standard
deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂ 0.05) when
compared to controls.

Poly(ADP-Ribose) Polymerase (PARP) Inhibition
A 50 mg/kg dose of cocaine at a 6 hour time point and a 300 mg/kg dose of
acetaminophen (APAP) at an 18 hour time point were determined to be the optimal doses and
time to analyze PARP inhibition. These optimal doses for cocaine and APAP were used to
evaluate PARP activity over a 24 hour period. These time points were chosen because the
highest levels of PARP activity were observed for the optimal dose at the observed time points
following treatment. A 10 mg/kg dose of 1,5-dihydroxyisoquinoline (DIQ), a PARP inhibitior,
was used to evaluate the effect of PARP inhibition on cocaine and APAP-induced hepatoxicity.
An ALT and PARP activity analysis was conducted for both toxicants.
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Figure 21. PARP Activity Fold Change for APAP. Increases in PARP activity following a 300
mg/kg dose of APAP at 2 hour, 6 hour, 18 hour, and 24 hour time points following an initial dose
(n=6).

A PARP inhibition ALT analysis for a 50 mg/kg dose of cocaine at the 6 hour time point
shows an elevation in serum ALT of 1677 IU/L following treatment. (See Figure 24.) A DIQ
injection administered concurrently with cocaine significantly reduced serum ALT to 201 IU/L.
DIQ administration at the 1 hour post cocaine treatment time point was not as effective in
reducing elevations in serum ALT.
DIQ treatment reduced cocaine-induced increased PARP activity by two fold. (See
Figure 25.) DIQ treatment administered one hour following cocaine was not as effective as
concurrent treatment. A larger reduction in PARP activity resulted from concurrent treatment of
DIQ when compared to the cocaine only dose group.
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Figure 22. Cocaine and APAP PARP Analysis: Bar Chart. A bar chart comparison of liver
PARP activity following a 50 mg/kg dose of cocaine and a 300 mg/kg dose of APAP was
conducted at 2 hour, 6 hour, 18 hour, and 24 hour time points following treatments (n=6).
Standard deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂
0.05) when compared to controls.

A 300 mg/kg dose of APAP significantly increased ALT 18 hours following treatment
with an observed measurement of 4003 IU/L. (See Figure 26). Concurrent treatment with DIQ
decreased that elevation to 856 IU/L. An APAP-induced increase in ALT was observed when
DIQ was administered 1 hour following APAP treatment. The elevation of ALT was also
reduced by DIQ treatment. The effect was not as robust when compared to concurrent DIQ
administration with cocaine treatment.
DIQ treatment decreased APAP-induced elevation of PARP activity by more than 4 fold
at 18 hours following treatment. (See Figure 27.) DIQ decreased PARP activity with concurrent
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treatment and treatment 1 hour following APAP dose. DIQ treatment 1 hour following APAP
was less effective than concurrent treatment.

Figure 23. Cocaine and PARP Analysis: Line Graph. A line graph comparison of PARP activity
for a 50 mg/kg dose of cocaine and a 300 mg/kg dose of APAP was conducted at 2 hour, 6 hour,
18 hour, and 24 hour time points following treatment (n=6).

A comparison of the effect of PARP inhibition on a 50 mg/kg dose of cocaine at a 6 hour
time point and a 300 mg/kg dose of APAP at an 18 hour time point was measured at the stated
time points. A DIQ dose was administered concurrently or 1 hour following drug treatment. (See
Figure 28.) Higher serum ALT was measured for APAP treatments when compared to cocaine.
The measured serum ALT for the both toxicants produced a significant decrease to elevations
with DIQ administration at the 0 hour post treatment time point. A larger decrease in serum ALT
was observed for APAP treatments with a concurrent DIQ administration. Increases for cocaine
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and APAP-induced samples with DIQ administration were observed at the 1 hour post initial
dose time point when compared to controls.

Figure 24. PARP Inhibition for Cocaine: ALT. A serum ALT PARP inhibition analysis
following a 50 mg/kg dose of cocaine at the 6 hour time point with the administration of a PARP
inhibitor, DIQ (n=6). Standard deviations are denoted with error bars. An (*) denotes statistical
significance at (p ˂ 0.05) when compared to controls.

A line graph comparison of serum ALT levels for PARP inhibition following a 50 mg/kg
dose of cocaine at a 6 hour time point and a 300 mg/kg dose of APAP at an 18 hour time point
was measured at the stated time points. Serum ALT levels were measured at a concurrent DIQ
dose and 1 hour post initial dose time points. (See Figure 29.) The line graph shows a very
similar pattern for both toxicants following DIQ-induced PARP inhibition when compared to
controls. Steeper declines and increases were observed for APAP samples. A large decrease in
serum ALT was observed with the concurrent administration of DIQ. A slight elevation was
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observed when DIQ was administered at the 1 hour time point for both toxicants when compared
to controls. A measurement for toxicant + DIQ at the 1 hour time point increases to serum ALT
levels observed for the toxicant only treatment group for both drugs.

Figure 25. PARP Activity Fold Change for PARP Inhibition for Cocaine. Decreases in PARP
activity following a 50 mg/kg dose of cocaine at a 6 hour time point of an initial dose with a
concurrent 10 mg/kg DIQ treatment and a DIQ treatment 1 hour following drug treatment. (n=6).

A PARP activity analysis for PARP inhibition was conducted with a 50 mg/kg dose of
cocaine at the 6 hour time point. (See Figure 30.) The cocaine treatment caused an activation of
PARP and a large increase in PARP activity of 1.36 IU/20 μg of protein when compared to
controls. A decrease in PARP activity was observed for a concurrent dose of DIQ at 0.74 IU/20
μg protein. DIQ administered 1 hour following cocaine treatment was not as effective with a
measurement of 1.09 IU/20 μg protein.
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Figure 26. PARP Inhibition for APAP: ALT. A serum ALT PARP inhibition analysis following
a 300 mg/kg dose of APAP at the 18 hour time point with the administration of a PARP
inhibitor, DIQ (n=6). Standard deviations are denoted with error bars. An (*) denotes statistical
significance at (p ˂ 0.05) when compared to controls.

PARP activity was measured following a 300 mg/kg dose of APAP at the 18 hour time
point following a concurrent DIQ treatment and a 1 hour following APAP treatment. (See
Figure 31.) The APAP treatment shows an activation of PARP and a large increase in PARP
activity at 1.52 IU/20 μg protein when compared to controls. A concurrent DIQ treatment
decreased PARP activity at 0.51 IU/20 μg protein. A slight increase in PARP activity was
observed when DIQ was administered 1 hour following APAP treatment time point at 1.10 IU/20
μg protein.
A combined analysis of PARP activity with PARP inhibition shows a relatively similar
trend for both cocaine and APAP. (See Figure 32.) PARP activity following APAP treatment
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resulted in a lower decrease in PARP activity with a concurrent dose of DIQ when compared to
cocaine. A larger increase was measured at 1 hour following APAP treatment time point than
cocaine. Both drugs resulted in a decrease in PARP activity with concurrent administration of
DIQ following treatments. Measurements observed at the 1 hour time point show that DIQ was
less effective in decreasing PARP activity for cocaine and APAP-induced hepatotoxicity.

Figure 27. PARP Activity Fold Change for PARP Inhibition for APAP. DIQ treatment resulted
in a fold decrease in PARP activity following a 300 mg/kg dose of APAP at the 18 hour time
point for a concurrent treatment and a 1 hour following drug treatment time points (n=6).

A line graph comparison of PARP activity with PARP inhibition shows a relatively
similar trend for both cocaine and APAP. (See Figure 33.) PARP activity following APAP
treatment resulted in a lower decrease in PARP activity with a concurrent dose of DIQ when
compared to cocaine. The line graph shows a similar pattern for cocaine and APAP treatments
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with DIQ when compared to controls. A significant decrease was observed with a concurrent
dose of DIQ for both toxicants. A slight elevation was observed 1 hour following treatment for
cocaine and acetaminophen treatments when compared to controls.

Figure 28. Cocaine and APAP PARP Inhibition: ALT Bar Chart. A bar chart comparison of a 50
mg/kg dose of cocaine at the 6 hour time point with the administration of DIQ concurrently or 1
hour following cocaine treatment (n=6) and a 300 mg/kg dose of cocaine at the 18 hour time
point with the administration of DIQ concurrently or 1 hour following APAP treatment (n=6).
Standard deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂
0.05) when compared to controls.

Glutathione
A glutathione (GSH) analysis was conducted for a 50 mg/kg dose of cocaine at the 6 hour
time point and a 300 mg/kg dose of acetaminophen (APAP) at the 18 hour time point to
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understand the role of GSH in PARP activity following the administration of a PARP inhibitor.
An analysis was conducted following cocaine and APAP treatments with a 10 mg/kg dose of
DIQ as a concurrent dose or 1 hour after following treatment. Glutathione was measured as a
ratio of GSH (reduced glutathione) to GSSG (oxidized glutathione) for each toxicant at the above
time points.

Figure 29. Cocaine and APAP PARP Inhibition: ALT Line Graph. A line graph comparison of a
50 mg/kg dose of cocaine at the 6 hour time point with the concurrent administration of DIQ or 1
hour following cocaine treatment (n=6) and a 300 mg/kg dose of APAP at the 18 hour time point
with the concurrent administration of DIQ or 1 hour time point following APAP treatment (n=6).

The glutathione ratio for 50 mg/kg dose of cocaine at the 6 hour time point decreased by more
than half when compared to controls to 9.10. (See Figure 34.) The ratio decreased for a
concurrent dose of DIQ. A concurrent administration of DIQ with cocaine treatment reduced the
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ratio to 1.96 when compared to animals treated with only cocaine. An increase in the oxidized to
reduced ratio of glutathione was observed for DIQ 1 hour following treatment at 4.17.

Figure 30. PARP Inhibition for Cocaine: PARP Activity. PARP activity for a 50 mg/kg dose of
cocaine at the 6 hour time point with the concurrent administration of DIQ or administration of
DIQ 1 hour following cocaine treatment (n=6). Standard deviations are denoted with error bars.
An (*) denotes statistical significance at (p ˂ 0.05) when compared to controls.

A glutathione analysis was conducted with a GSH to GSSG ratio for a 300mg/kg dose of
APAP at an 18 hour time point to determine the role of glutathione in PARP activity. (See Figure
35.) An increase in the ratio was measured following APAP treatment at 3.29 and at 5.40 for a
concurrent dose of DIQ when compared to 1 hour following treatment. A decrease in the
GSH/GSSG ratio was observed with a DIQ dose administered 1 hour following treatment.
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Figure 31. PARP Inhibition for APAP: PARP Activity. PARP activity for a 300 mg/kg dose of
APAP at the 18 hour time point with the concurrent administration of DIQ or administration of
DIQ 1 hour following cocaine treatment (n=6). Standard deviations are denoted with error bars.
An (*) denotes statistical significance at (p ˂ 0.05) when compared to controls.

A comparison of the ratio of GSH to GSSG for a 50 mg/kg dose of cocaine and a 300
mg/kg dose of APAP with a concurrent administration of DIQ and 1 hour following treatment
for both drugs reveals significant differences in the measured ratio. (See Figure 36.) A higher
ratio was measured for control liver samples following cocaine treatments than for APAP
treatments. The GSH to GSSG ratio decreased in liver samples following cocaine treatment. A
concurrent dose of DIQ showed a decrease for the cocaine samples while an increase in the ratio
was observed for the APAP samples. A similar inverse relationship was observed for DIQ
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Figure 32. PARP Inhibition for Cocaine and APAP: PARP Activity Bar Chart. A bar chart
comparison of PARP activity for a 50 mg/kg dose of cocaine at the 6 hour time point and a 300
mg/kg dose of APAP at the 18 hour time point with the concurrent administration of DIQ or
administration of DIQ 1 hour following cocaine treatment Standard deviations are denoted with
error bars. An (*) denotes statistical significance at (p ˂ 0.05) when compared to controls.

administration 1 hour following cocaine and APAP treatments. The inverse relationship observed
for cocaine and APAP may express an independent relationship with glutathione and PARP
activity in the presence of a PARP inhibitor.
The line graph for a glutathione ratio comparison following cocaine and APAP
treatments shows an inverse relationship for both drugs with a concurrent administration of DIQ
or 1 hour following treatment. (See Figure 37.) There is no clear linear pattern for the glutathione
ratio following cocaine or APAP treatments with administration of DIQ. The glutathione ratio
following cocaine and APAP treatments show individual linear trends that may suggest an
independent relationship for PARP activity with glutathione for cocaine and APAP.
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Figure 33. PARP Inhibition for Cocaine and APAP: PARP Activity Line Graph. A line graph
comparison of PARP activity for a 50 mg/kg dose of cocaine at the 6 hour time point and a 300
mg/kg dose of APAP at the 18 hour time point with the concurrent administration of DIQ or
administration of DIQ 1 hour following cocaine treatment Standard deviations are denoted with
error bars. An (*) denotes statistical significance at (p ˂ 0.05) when compared to controls.

DNA Fragmentation
A 1.6% agarose gel was used to conduct a DNA fragmentation analysis for a 50 mg/kg
cocaine dose at a 6 hour time point and a 300 mg/kg dose of APAP at an 18 hour time point. A
10 mg/kg dose of the PARP Inhibitor of DIQ was administered concurrently with cocaine and
APAP treatments or at 1 hour following cocaine and APAP treatments. DNA was analyzed from
collected liver samples for any fragments, tears, or shredding of DNA in each of the treatment
samples. Herring sperm DNA was used as a positive control to show the presence of DNA with
no fragments. An expression of fragmented DNA may suggest evidence of apoptosis as the
resultant outcome of drug toxicity as opposed to necrosis.
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Figure 34. Glutathione Analysis for Cocaine. A 50 mg/kg dose of cocaine at a 6 hour time point
measured a ratio of reduced glutathione to its oxidized form of GSSG. Measurements were
conducted for concurrent administration of DIQ and 1 hour following treatment (n=6). Standard
deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂ 0.05) when
compared to controls.

A DNA fragmentation analyses was conducted to determine the impact of a cocaine
treatment with a PARP inhibitor on DNA. (See Figure 38.) The resultant DNA fragmentation
results show no cocaine treatment samples contained fragmented DNA. The results suggest that
apoptosis is most likely not an outcome for cocaine-induced hepatotoxicity for a 50 mg/kg dose.
Results also suggest that DIQ administered concurrently or 1 hour following cocaine treatment
did not result in DNA fragmentation.
Fragmented DNA was analyzed for a 300 mg/kg APAP dose with a 10 mg/kg DIQ PARP
inhibitor dose. (See Figure 39.) The resultant DNA fragmentation results shows no samples for
APAP only treatments, APAP administered concurrently with DIQ, or 1 hour following
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treatment resulted in fragmented DNA. The results suggest that apoptosis is likely not an
outcome for APAP-induced hepatotoxicity. This also suggests that DIQ administered
concurrently or 1 hour following APAP treatment did not result in DNA fragmentation.

Figure 35. Glutathione Analysis for APAP. A 300 mg/kg dose of APAP at an 18 hour time point
measured a ratio of glutathione to its oxidized form of GSSG. Measurements were conducted for
concurrent administration of DIQ and 1 hour following treatment (n=6). Standard deviations are
denoted with error bars. An (*) denotes statistical significance at (p ˂ 0.05) when compared to
controls.

A comparison of analysis for DNA fragmentation was conducted to express any resultant
fragmentation for a 50 mg/kg dose of cocaine or a 300 mg/kg dose of APAP with a 10 mg/kg
dose of DIQ at a 0 hour or 1 hour time point. (See Figure 40.) DNA fragmentation results show
no fragmented DNA was observed following cocaine and APAP treatment with a concurrent
DIQ dose or a DIQ dose 1 hour following treatment. These results also conclude that apoptosis is
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not likely to be the ending result for cell damage resulting from PARP activation following
cocaine and APAP treatments.

Western Blot
A western blot analysis was conducted for a 50 mg/kg cocaine or a 300 mg/kg dose of
APAP with a 10 mg/kg concurrent dose of DIQ and 1 hour following treatment to analyze the
expression of PARP in cocaine and APAP-induced liver samples. A protein ladder was used to
measure the molecular weight of PARP at 116 kDa. PARP- High Specific Activity Enzyme
(PARP-HSA) was used as a positive control to show the presence of PARP.

Figure 36. Glutathione for Cocaine and APAP: Bar Chart. A comparison of the glutathione ratio
of GSH to GSSG for a 50 mg/kg dose of cocaine and a 300 mg/kg dose of APAP with the PARP
inhibitor DIQ administered concurrently or 1 hour following drug treatment (n=6). Standard
deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂ 0.05) when
compared to controls.
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Figure 37. Glutathione for Cocaine and APAP: Line Graph. A comparison of the glutathione
ratio of GSH to GSSG following a 50 mg/kg dose of cocaine and a 300 mg/kg dose of APAP
with a concurrent dose of PARP inhibitor DIQ or a DIQ dose 1 hour following treatments (n=6).
Standard deviations are denoted with error bars. An (*) denotes statistical significance at (p ˂
0.05) when compared to controls.

A western blot analysis was conducted for a 50 mg/kg cocaine with a concurrent 10
mg/kg dose of DIQ and 1 hour following treatment. (See Figure 41.) Lane 1 was a positive
control of PARP-HSA with a molecular weight measuring at 116 kDa. Lane 2 was a protein
ladder used to determine the molecular weight of PARP protein. Lane 3 (cocaine + DIQ
administered 1 hour following treatment), lane 4 (cocaine + DIQ administered 1 hour following
treatment), and lane 8 (cocaine treatment only) show light signals of PARP protein at 116 kDa,
likely due to a weak transfer to nitrocellulose. Lane 5 (cocaine + a concurrent DIQ dose) and
lane 7 (cocaine treatment only) shows strong signals of PARP protein at 116 kDa. Lane 6
(cocaine + a concurrent DIQ dose) does not show any strong PARP protein signals, likely due to
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a bad transfer. This is likely due to low signaling or weak transfer. The cocaine saline control in
lane 9 and the negative control (RIPA buffer) in lane 10 do not express any PARP signaling at
116 kDa. Lanes expressing PARP protein signaling express activation and presence of PARP
activity observed from cocaine and APAP treatment with DIQ liver samples.
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Figure 38. DNA Fragmentation: Cocaine. A 50 mg/kg dose of cocaine + 10 mg/kg DIQ dose
concurrently or 1 hour following treatment in a 1.6% agarose gel. (1) (-) control (H2O), (2) (+)
control (Herring Sperm DNA), (3) loading control (resuspension buffer), (4) saline control, (5)(6) cocaine dose only, (7)-(8) cocaine + concurrent DIQ dose, (9)-(10) cocaine + DIQ dose 1
hour following treatment.

A western blot analysis was conducted for a 300 mg/kg APAP and a 10 mg/kg concurrent
DIQ dose and a DIQ dose 1 hour after treatment. (See Figure 42.) Lane 1was a positive control
of PARP-HSA expressing a low signal with a molecular weight measuring at 116 kDa. This is

68

likely due to low concentration of protein transferred during the assay. Lane 2 shows a protein
ladder used for measuring molecular weight of PARP protein at 116 kDa. Lanes 3 & 4 (APAP +
DIQ 1 hour following treatment ), lanes 5 & 6 (APAP + a concurrent DIQ dose, and lanes 7 & 8
(APAP treatment only) express strong signals of PARP protein at 116 kDa. Lane 9 (APAP saline
control) and lane 10 (negative control) show no signals of PARP protein at 116 kDa. Lanes
expressing PARP protein signaling express activation and presence of PARP activity expressed
with liver samples used for analysis.
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Figure 39. DNA Fragmentation: APAP. A 300 mg/kg dose of APAP + 10 mg/kg DIQ dose
concurrently or 1 hour following treatment in a 1.6% agarose gel. (1) (-) control (H2O), (2) (+)
control (Herring Sperm DNA), (3) loading control (resuspension buffer), (4) saline control, (5)(6) APAP dose only, (7)-(8) APAP + concurrent DIQ dose, (9)-(10) APAP + DIQ dose 1 hour
following treatment .
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Figure 40. DNA Fragmentation: Cocaine & APAP. A 50 mg/kg dose of cocaine and a 300
mg/kg dose of APAP + 10 mg/kg concurrent DIQ dose and 1 hour following drug treatment in
1.6% agarose gel. (1) APAP + DIQ 1 hour after treatment, (2) cocaine + DIQ 1 hour after
treatment, (3) APAP + a concurrent DIQ dose, (4) cocaine + a concurrent DIQ dose, (5) APAP
treatment only, (6) cocaine treatment only, (7) APAP saline control, (8) cocaine saline control,
(9) (+) control (Herring Sperm DNA), (10) (-) control (H2O).
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Figure 41. Western Blot: Cocaine. A 50 mg/kg dose of cocaine at the 6 hour time point + a
concurrent 10 mg/kg DIQ dose and a DIQ dose1 hour following treatment in 4-10.5% Trisglycine polyacrylamide gel. (1) (+) control, PARP-HSA (2) protein ladder, (3)-(4) cocaine +
DIQ 1 hour following treatment (5)-(6) cocaine + a concurrent DIQ dose, (7)-(8) cocaine
treatment only, (9) cocaine saline control, (10) (-) control, RIPA buffer.
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Figure 42. Western Blot: APAP. A 300 mg/kg dose of APAP at the 18 hour time point + a
concurrent 10 mg/kg DIQ dose and a DIQ dose1 hour following treatment in 4-10.5% Trisglycine polyacrylamide gel. (1) (+) control, PARP-HSA (2) protein ladder, (3)-(4) APAP + DIQ
1 hour following treatment, (5)-(6) APAP + a concurrent DIQ dose, (7)-(8) APAP treatment
only, (9) APAP saline control, (10) (-) control, RIPA buffer.
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CHAPTER FIVE:
DISCUSSION

This experiment has shown that cocaine and acetaminophen-induced hepatotoxicity can
activate poly(ADP-ribose) polymerase (PARP) activity in the liver. In the presence of an
overdose, cocaine and acetaminophen (APAP) can produce elevations in PARP activity. The use
of a PARP inhibitor following cocaine and APAP treatment, 1,5-dihydroxyisoquinoline (DIQ),
was shown to reduce PARP activity in the liver. Cocaine and APAP-induced hepatotoxicity
produced from cocaine and APAP treatments resulted in widespread liver damage producing
significant elevations in serum ALT and increases in PARP activity in liver tissues.
A dose-response analysis conducted following a cocaine treatment produced an optimal
dose of 50 mg/kg to evaluate cocaine-induced hepatotoxicity. While doses lower than 50 mg/kg
produced significantly elevated serum alanine aminotransferase (ALT) levels, a 60 mg/kg dose
caused severe hemorrhaging and resulted in a decrease in measured serum ALT that was likely
due to the inability of the metabolism of cocaine following treatment. The measured ALT for the
60 mg/kg dose is inconsistent with Roth et al. and McCluskey et al. that chose a 60 mg/kg dose
to analyze for experiments (McCluskey, Harbison, Sava, Johnson, Harbison, 2012). No studies
have conducted a temporal analysis to determine the optimal time when PARP activity is highest
for cocaine-induced hepatotoxicity. A comparative temporal analysis was conducted for PARP
activity over a 24 hour period at a 2 hour, 6 hour, 18 hour, and 24 hour time point were serum
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ALT was analyzed for any indications of cocaine-induced hepatotoxicity. While serum ALT
levels increased incrementally at each time point, the highest ALT levels were observed at the 24
hour time point. Results from PARP analysis following cocaine treatment showed the most
activity was observed at the 6 hours following treatment. It is expected for biochemical results to
be delayed due to the time it takes to for the drug to be metabolized by the liver. Results suggest
that time may play a role in the difference between cocaine metabolism in the liver and the time
for activation of PARP activity following treatment. These differences may exist with an acute
and chronic cocaine dose. Scobie et al. measured elevations in PARP activity following a
repeated cocaine dose from a single endpoint sacrifice time point in the brain. This may suggest
that while elevations to PARP activity may be observed at a number of time points, the time
point for peak PARP activity may exist during a specific period of time following cocaine
treatments (Scobie, et al., 2014).
A dose-response analysis conducted for acetaminophen showed small elevations in serum
ALT observed at the lower dose groups of 75 mg/kg and 150 mg/kg. Significant elevations in
serum ALT were measured with a 200 mg/kg and 300 mg/kg dose group. A 300 mg/kg dose was
chosen as the optimal dose to conduct a PARP analysis due to significant elevations in serum
ALT observed and low mortality. A temporal analysis conducted by Cover at al. and Gujral et al.
produced similar results for a 300 mg/kg dose of APAP of an increase in serum ALT over time
an observed time period (Gujral, Knight, Farhood, Bajt, Jaeschke, 2002; Cover et al., 2005a). An
analysis of a 12 hour observation time by Cover at al. and a gap between hours 6 and 24 for
Gujral et al. suggest that while increases to serum ALT were observed as time progressed, some
differences in serum ALT may have been observed at time points not observed during the study.
These gaps in measurements may potentially impact analyzing PARP activity, as there may be
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elevations in activity outside of the measured parameters that could suggest other periods of peak
PARP activity. Results gathered from this study suggest that PARP activity and serum ALT may
be independent of one another in reference to time. While increases in PARP activity following
treatment may be observed, the importance of determining peak PARP activity may provide
answers to more accurate administration of PARP inhibitors in the future.
A PARP inhibitor efficacy analysis was conducted with DIQ for acetaminophen and
cocaine. Although DIQ is not a potent PARP inhibitor, a reduction in PARP activity was
observed with a concurrent DIQ administration and a DIQ administration one hour following
drug treatment. A serum ALT analysis for both toxicants testing the efficacy of the DIQ in
reducing liver damage shows that a significant reduction in serum ALT was observed with a
concurrent administration of DIQ, followed by a small increase observed one hour following
treatment. Significant increases observed at the DIQ one hour following treatment time point
shows that time does play a role in the reduction of potential liver damage that may result from
drug-induced toxicity. While a delay in biochemical samples is expected with drug metabolism
of the liver, serum ALT results alone may not prove effectiveness of a PARP inhibitor. A similar
trend was observed with PARP activity following an acetaminophen and cocaine treatment to
suggest that DIQ is effective at reducing PARP activity.
McCluskey et al. analyzed the effectiveness of DIQ with a 60 mg/kg cocaine dose on the
liver. Reductions in serum ALT and PARP activity were measured in liver tissue samples. Study
results also measured an increase in serum ALT at the one hour post initial dose time point.
These results suggest that the effectiveness of a PARP inhibitor is impacted by time of
administration. DIQ is most effective at inhibiting PARP activity and decreasing serum ALT
levels when administered concurrently with a treatment dose (McCluskey, Harbison, Sava,
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Johnson, Harbison, 2012). The significant differences in serum ALT for the measured PARP
inhibitor time points suggest that while there is a window of time to reduce drug-induced liver
injury, that window of time is very small. Results from this study for a 50 mg/kg cocaine dose
produced similar results measuring a large increase in serum ALT from the DIQ administration
concurrently with cocaine treatment to the one hour following treatment time point. No temporal
analysis was conducted for PARP activity to determine the role of time on peak PARP activity.
A similar analysis was conducted for a 300 mg/kg dose of APAP with a concurrent 3aminobenzamide (3-AB) dose by Cover et al. and Dӧnmez et al. (Dӧnmez, Uysal, Poyrazoglu,
Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015; Cover et al., 2005a). Both studies revealed a
decrease in serum ALT levels. An increase in survival, glutathione, and PARP activity were
observed for animals treated with 3-AB when compared to APAP treatment only animals.
Results from this study produced similar results for PARP inhibition with DIQ administration for
a 300 mg/kg APAP dose.
The results gathered from this study for the role of cocaine and acetaminophen on PARP
inhibition with administration of DIQ on PARP activity supports studies that show DIQ protects
against hepatotoxic events resulting from drug-induced toxicity (Cover et al., 2005a; McCluskey,
Harbison, Sava, Johnson, Harbison, 2012; Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker,
Kaldirim, Korkmaz, 2015; McCluskey, Sava, Harbison, Muro-Cacho, Johnson, Ping, Harbison,
2011; Shi et al., 2012; Banasik, Stedeford, Strosznajder, Takehashi, Tanaka, Ueda, 2011).
Cocaine and acetaminophen treatment produced an activation of PARP where elevated levels of
PARP activity were also observed. Elevated levels of PARP activity and serum ALT suggest that
significant damage to the liver resulted from toxic doses of acetaminophen and cocaine.
Measurements for acetaminophen produced significantly higher measurements for ALT and
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PARP activity when compared to cocaine. These were not expected results for acetaminophen
when compared to cocaine, however, this may also be due to the route of administration for the
toxicant dose. Administration of the 300 mg/kg dose of acetaminophen via the intraperitoneal
route may have elicited a more extreme response due to metabolism of the drug and its ability to
enter into the blood stream where toxic metabolites are produced in the liver.
Western blot analysis produced similar evidence with measurements of PARP weighing
at 116 kDa was expressed for cocaine and acetaminophen. This supports elevations in serum
ALT and PARP activity measured that would suggest activations of PARP activity following
cocaine and acetaminophen treatment. Results also revealed the presence of non-specific binding
among various proteins at various molecular weights. An analysis determining the cleavage of
PARP may have provided a more in-depth understanding of the role of PARP and how it may
differ following cocaine and acetaminophen treatment. A caspase-3 detection analysis would
confirm whether apoptosis or necrosis was the hepatotoxic cell death pathway resulting in the
observed cytotoxic damage.
A temporal analysis was conducted to determine the optimal time when PARP activity
was highest following cocaine and acetaminophen treatments. A serum ALT analysis over a 24
hour period revealed that while elevations were observed for both drugs during the observed time
period, significant differences were observed at each measured time point. The temporal analysis
for PARP activity was also found to produce significantly different measurements at each
observed time point. Cover et al. analyzed the role of time on a 300 mg/kg dose of
acetaminophen over a 12 hour period (Cover et al., 2005a). Results to ALT and PARP activity
revealed similar results in showing increases to activity observed over time. PARP activity
measured for acetaminophen produced a delayed reaction over the observed period which were
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also observed through results gathered from this study. Results for PARP activity following
acetaminophen and cocaine treatments differed over the observed 24 hour time period. While
acetaminophen produced delayed elevations in PARP activity occurring at the later time points
within the observed 24 hour period. However, PARP activity results for cocaine produced
varying results in activity at the earlier time points with decreases in activity observed at the later
time points within the 24 hour observation period.
A temporal analysis was also conducted for the concurrent administration of the DIQ
PARP inhibitor and 1 hour following treatment for both toxicants. A similar analysis was
conducted by McCluskey et al. for a 60 mg/kg dose with cocaine with DIQ at a 0 hour, 1 hour,
and 2 hours following treatment time point (McCluskey, Harbison, Sava, Johnson, Harbison,
2012). Similar results were measured for DIQ and its ability to provide protection against
cocaine-induced hepatotoxicity events following cocaine treatment. The largest reduction in
serum ALT was observed with a concurrent administration of DIQ, followed by large increases
observed at the 1 hour following treatment time point. Similar results were gathered for cocaine
and acetaminophen with a similar analysis for DIQ observed with a concurrent dose and a dose 1
hour following treatment time points. Reductions in PARP activity were observed with a
concurrent DIQ administration and 1 hour following treatment for cocaine and acetaminophen.
While a larger reduction in PARP activity was observed with concurrent administration of DIQ,
results for both toxicants measured a much larger reduction for a concurrent administration of
DIQ with acetaminophen treatment than cocaine treatment.
A glutathione analysis produced the ratio of reduced to oxidized glutathione. Ratios were
gathered for a 50 mg/kg dose of cocaine at a 6 hour time point or a 300 mg/kg dose of
acetaminophen at an 18 hour time point with a concurrent administration of DIQ and 1 hour
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following treatment. Results from this analysis revealed a potential independent relationship for
glutathione following cocaine and acetaminophen with DIQ administration. Alternatively,
glutathione ratio measurements for the control group for acetaminophen were significantly lower
than the toxicant dose group. Glutathione ratios measured for cocaine treated animals express
that there may be a decrease in glutathione caused by cocaine and that DIQ may provide a
delayed protection against hepatotoxic events at the 1 hour following treatment time point.
Results gathered following acetaminophen treatment may suggest that the reactive metabolite,
acetaminophen-glutathione conjugate (APAP-SG), produced during oxidation may produce toxic
effects that may inhibit glutathione reductase activity. The inhibition of glutathione reductase by
APAP-SG may suggest a competitive enzyme mechanism that could contribute to false
elevations observed with acetaminophen treatments (Nýdlova, Vrbová, Česla, Jankovičová,
Ventura, Roušar, 2013).
Gross pathology tissue samples following cocaine and APAP treatment at the 24 hour
time point. The cocaine treatment samples display motteling on the surface with hemorrhaging
observed on the surface of the liver. Resultant observations for the cocaine sample suggest that
necrosis cell death is the pathway that results from cocaine-induced hepatotoxicity (Evans, 1983;
Roth, Harbison, James, Tobin, Roberts, 1992; Thompson, Shuster, Shaw, 1979). A similar
analysis was conducted for acetaminophen with significantly damaging impacts on the liver.
Observations revealed a substantial amount of hemorrhaging on the surface of the liver. The
results gathered from observing samples following acetaminophen treatment also suggest that
necrosis is the cell death pathway for acetaminophen induced toxicity (Cover et al., 2005a;
Dӧnmez, Uysal, Poyrazoglu, Er Ӧztas, Türker, Kaldirim, Korkmaz, 2015; Mitchell, Jollow,
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Potter, Davis, Gillette, Brodie, 1973; Williams, Koerner, Lampe, Farhood, Jaeschke, 2011;
Gujral, Knight, Farhood, Bajt, Jaeschke, 2002).
A DNA fragmentation analysis following cocaine and acetaminophen treatment
evaluated the presence of fragmented DNA with PARP inhibited liver samples. Results from
cocaine and cocaine + DIQ samples revealed no fragments to DNA in observed samples. Similar
results were observed for APAP and APAP + DIQ samples. These results differ from Cover et al.
that found the presence of fragmented DNA along with increases observed in fragmentation as
time from initial dose increased (Cover et al., 2005a). While DNA fragmentation is considered to
be a precursor for apoptotic signaling, presence of fragmented DNA has also been shown to
produce necrotic cell death in liver cells. Some apoptotic cell death has been observed in the
presence of acetaminophen induced drug toxicity (Cover et al., 2005a; Ray, Kamendulis, Gurule,
Yorkin, Corcoran, 1993). However, recent studies analyzing acetaminophen hepatotoxicity have
ruled out apoptosis as a cell death pathway (Cover et al., 2005a; Gujral, Knight, Farhood, Bajt,
Jaeschke, 2002; Mitchell, Jollow, Potter, Davis, Gillette, Brodie, 1973).
Some possible limitations to this study include analyses used to determine PARP activity
and cell death resulting from activation of PARP activity. The detection of glutathione and its
role in PARP activity can be detected to determine the impacts of drug toxicity on cellular
activity. While results may vary depending upon the toxicant, glutathione is expected to be
depleted within the cell during toxic exposures to drugs and chemicals. The independent results
gathered from this analysis with cocaine and acetaminophen presented alternative results that
may distort the true role of glutathione on PARP activity. A western blot analysis analyzing the
cleavage of PARP may have helped to better define the role of PARP activity following cocaine
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and APAP treatments. More in-depth analyses for PARP activity may detect alternatives to cell
death with drug-induced toxicity with administration PARP inhibitors.
There are a number of analyses that can be conducted to better understand the role of
PARP activity in the presence of drug toxicity. Comparisons of drugs and chemicals help to
better understand the metabolism of toxic metabolites activating PARP activity in the liver.
Assays such as lipid peroxidation and caspase-3 can help to determine cell death pathways of
necrosis or apoptosis for chemicals and drugs. Conducting analyses to understand that activity of
PARP proteins during various stages of toxicity may help to understand better methods at
inhibiting PARP activity. Evaluating the role of time with PARP activity is important to better
understand the optimal time to supply PARP inhibitors in order to help elicit maximum potential
when responding to hepatotoxic events.
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CHAPTER SIX:
CONCLUSION

This study helped to prove the efficacy of the PARP inhibitor, DIQ, with cocaine and
APAP-induced hepatotoxicity. Conducting a dose-response analysis following cocaine and
acetaminophen treatment helped to determine the optimal dose that would elicit hepatotoxicity
but not cause mortality. Results from this study helped to show that while there may be multiple
doses that may contribute to significant elevations in serum ALT, determining the maximum
dose to elicit PARP activity is key to determining the efficacy of potential PARP inhibitor
treatment. Incorporating the element of time into an analysis will help to better understand PARP
activity in order to produce the maximum effects from administration of PARP inhibitors. Time
will also help to better understand the role of PARP activity for acute and chronic doses of drugs
during drug-induced hepatotoxicity. Results from this study shows that time plays a major role in
drug-induced hepatotoxicity following cocaine and acetaminophen treatment and the efficacy of
PARP inhibitors.
The debate with apoptosis and necrosis cell death pathways helps to provide areas for
future research between a number of drugs and chemicals. Determining intermediate
impairments to cell function may lead to prevention of widespread damage resulting from these
cell death pathways. As research for the efficacy of PARP inhibitors is studied to better
understand the role of the production of toxic metabolites on PARP activity, new methods to
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evaluate and understand metabolic differences that may exist for drugs and chemicals will help
to propel research with PARP activity into new directions. Although drug-induced toxicity has
been studied for a number of decades, creating new methods to evaluate cellular function as
PARP is activated helps to allow for comparisons with various drugs and chemicals that will
help with determining new methods to inhibit PARP activity in the future. A better
understanding of the role of PARP activity in drug-induced hepatotoxicity may help to reduce
widespread damage to the liver and may help to potentially save life by increasing the window of
time for which an individual may be able to seek medical assistance.
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